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Figure 1.1 The menstrual cycle and hormones. A schematic of the hormone levels 
throughout the menstrual cycle. LH = Luteinising Hormone, FSH = Follicle Stimulating 
Hormone, WOI = Window of Implantation. 
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Figure 1.2 Overview of the endometrium during the menstrual cycle. Abstract 
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1.2 Endometriosis: The disease, diagnosis and treatments 
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Lining of Pelvic Cavity
Figure 1.3 Schematic of 
retrograde menstruation 
and endometriosis. A 
diagram of half of the 
human uterus lined with 
endometrial tissue. 
Fragments or cells of the 
endometrium travel via 
the fallopian tube into the 
pelvic cavity. 
Endometriotic lesions are 
present on the outside of 
the uterus and its 
surrounding environment. 
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Figure 1.4 Overview of Epigenetic modifications. Abstract representation of epigenetic 
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Table 1.1 H3K27me3 and EZH2 in the Endometrium. Summary of the literature with 
regards to H3K27me3 and EZH2 during the menstrual cycle and in cell culture. Method used 
for detection: EpiQuick = specific assay kit, WB = Western Blot, IHC = 
Immunohistochemistry, IF= Immunofluorescence, RT-qPCR = Reverse Transcription 










Whole tissue Reference Stomal Cells Epithelilal Cells Reference









No Change          
(WB and IF)
EZH2 Decreased        (WB)








Decreased           
(WB and IF)







Grimaldi et al. 
2016
Endometrium Cell Culture
Proliferative Phase vs Secretory Phase
Estrogen + 
Progesterone Reference
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Table 1.2 DNMTs in the Endometrium. Summary of the literature with regards to DNMT1, 
DNMT3A and DNMT3B during the menstrual cycle and in cell culture. Method of analysis: 
IHC = Immunohistochemistry, WB= Western Blot, RT-qPCR = Reverse Transcription 
quantitative Polymerase Chain Reaction 
	
	
























Reference Estrogen + Progesterone Reference
DNMT1 No Change (WB)
DNMT3A No Change (WB)
DNMT3B Decreased after 6 days (WB)
DNMT1
Decreased /            
No Change /  
Increased 
Yamagata et al. 2009 / 
Vincent et al. 2011 / 
van Kaam et al. 2011
Lowest at Mid-
Secretory /    
No Change
No Change / No Change / 
Decreased after 48 hours/ 
Increased after 24hours
Dyson et al. 2015 / 
Yamagata et al. 2009 / 
Vincent et al. 2011 /     
van Kaam et al. 2011 
DNMT3A Decreased / Decreased
Yamagata et al. 2009 / 
Vincent et al. 2011
Lowest at Mid-
Secretory /    
No Change
No Change /            
Decreased after 8 days /       
or after 48hours
DNMT3B
Trend to Decrease / 
Trend to Decrease / 
Decreased
Yamagata et al. 2009 / 
van Kaam et al. 2011 / 
Vincent et al. 2011
No Change / 
No Change
Decreased after 6 days /    
after 8 days /                            
or after 48hours
mRNA   
(RT-qPCR)
Dyson et al. 2015 / 
Yamagata et al. 2009 / 













   










Protein Yamagata et al. 2009 Dyson et al. 2015
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Table 1.3 Histone Modifications in Endometriosis. Summary of the literature with regards 
to histone modifications and EZH2 expression comparing ectopic lesions, eutopic tissue from 
patients with endometriosis and eutopic tissue from control patients. Method for analysis: 









Eutopic Endometriosis         
v                            
Lesions
Reference
Eutopic Control                                 
v                                                 
Lesions
Reference
Eutopic Control                                 
v                                                  
Eutopic Endometriosis
Reference
H3ac No Change (EpiQuick) /          No Change (EpiQuick)
Decreased in Lesions (EpiQuick)/                                    
No Change (EpiQuick)
Monteiro et al. 2014/ 
Xiaomeng et al. 2013
Trend to decreased in Eutopic 
Endometriosis (EpiQuick) /                                      
No Change (EpiQuick)
Monteiro et al. 2014/ 




No Change (EpiQuick) Decreased in Lesions (EpiQuick) Monteiro et al. 2014 Decreased in Eutopic Endometriosis (EpiQuick) Monteiro et al. 2014
H3K4me Increased in L (EpiQuick) Increased in Lesions (EpiQuick) Monteiro et al. 2014
Increased in Eutopic 
Endometriosis (EpiQuick) Monteiro et al. 2014
H3K9me   
or 
H3K9me3
No Change (EpiQuick) / 
Decreased in L 
(EpiQuick)
Increased in Lesions (EpiQuick)/                
(IHC) /                                           
(IHC) /                                    
Decreased in Lesions (EpiQuick)
Monteiro et al. 2014/ 
X. Liu et al. 2018 /     
Q. Zhang et al. 2017/ 
Xiaomeng et al. 2013
No Change (EpiQuick) /      
Increased in Eutopic 
Endometriosis (IHC)/                     
No Change (EpiQuick)
Monteiro et al. 2014/ 
Q. Zhang et al. 2017/ 





Increased in L (EpiQuick) /      
(IHC) /                                           
(IHC) 
Monteiro et al. 2014/ 
X. Liu et al. 2018 /     
Q. Zhang et al. 2017 
Increased in Eutopic 
Endometriosis (EpiQuick) /      
(IHC)
Monteiro et al. 2014/ 
Q. Zhang et al. 2017 
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Paper Model System Number of samples Menstrual cycle Loci or Global Technique
BS 
treatment Comments
Wu et al. 2005 Controls= 4, Endometriosis = 6 Histology HOXA10 MSP and Bisulphite sequencing Yes Increase in methylation in endometriosis
Wu et al. 2006
Controls= 4 (M= 2, P= 2), Endometriosis 
Ectopic= 8 (M=1, P=6, S=1), Endometriosis 
Eutopic= 6 (P=5, S=1)
Histology PGR-B MSP and Bisulphite sequencing Yes Heterogensous methylation in endometriosis
Kulp et al.2016 Controls = 7, Endometriosis Eutopic = 27 NA HOXA10 Sequenom MassARRAY Yes Decrease in methylation in endometriosis
Kim et al. 2007 Control Eutopic baboons= 6, Endometriosis Eutopic baboons= 6 MS, E2 levels HOXA10 MSP Yes
Increase in methylation in 
endometriosis
Lee et al. 2009 Control mice = 7, Surgical endometriosis mice= 8 NA HOXA10 MSP and Bisulphite sequencing Yes
Increase in methylation in 
endometriosis
Li et al. 2016 Control mice =6, Surgical endometriosis ectopic mice= 6 NA
HOXA10 and 
PGR
EpiTect Methyl II Assay No Increase in methylation in endometriosis
Borghese et al. 2010 Endometriosis Eutopic= 20  Endometriosis Ectopic= 20 (paired)
Luteal phase, 
Histology Global
MeDIP on Affymetrix GeneChip 
Human Promoter 1.0R No
229 - 108 differentially 
methylated regions depending 
on severity of endometriosis
Naqvi et al. 2014 Controls= 6, Endometriosis Eutopic= 7 NA Global Infinium HumanMethylation27k Yes 120 differentially methylated genes
Houshdaran et al. 
2016
Controls = 16 (P= 6, ES= 5, MS= 5) , 
Endometriosis Eutopic = 17 (P= 4, ES= 7, 
MS= 6)
Histology, E2 
and P4 levels Global Infinium HumanMethylation27k Yes
234 differentially methylated 
CpGs
Saare et al. 2016
Control= 24 (M= 1, P = 3, ES= 1, MS= 17, 
LS= 2), Endometriosis Eutopic=31 (M= 4, P 
= 2, ES= 7, MS= 9, LS= 9)
Self reported 
history and LH 
surge
Global Infinium HumanMethylation450k Yes 28 differentially methylated regions
Rahmioglu et al. 
2017
Controls = 8, Endometriosis Eutopic= 8, 
Endometriosis Ectopic= 8
Self reported, 
phase NA Global Infinium HumanMethylation450k Yes
3,915 differentially methylated 
probes between paired 
eutopic and ectopic






re Stromal cell culture from control and 
endometriosis: untreated= 6, post in vitro 
decidulisation= 6















Table 1.4 DNA methylation in Endometriosis. Summary of the literature with regards to DNA methylation in Endometriosis. M= Menstrual phase, 
P = Proliferative phase, S= Secretory phase, ES = Early Secretory phase, MS = Mid Secretory phase, LS = Late Secretory phase, NA = Not Available 
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While it is perhaps not too surprising that ectopic lesions differ in their methylation 
profile from eutopic control tissue, it may be more meaningful to investigate whether 
the eutopic endometrium of patients already has some pre-existing epigenetic changes 
that may predispose the cells to be more adhesive or tolerant to a foreign tissue 
environment. Some studies have indeed looked at methylation changes associated with 
eutopic endometrium from patients with or without endometriosis (Table 1.4, 
Houshdaran et al. 2016; Naqvi et al. 2014). These show that there are a number of 
differentially methylated CpGs, which are associated with expression changes of the 
associated gene (Houshdaran et al. 2016; Naqvi et al. 2014). These included genes 
related to inflammation and the immune response, cell cycle and steroid hormone 
response. The majority of differential methylation occurred in the mid-secretory phase 
compared to the early secretory or proliferative phases (Houshdaran et al. 2016). How 
robust and common these changes are in other patient cohorts remains to be 
established, as only 4 to 7 samples were used per group in this study. 
Despite these changes in DNA methylation status at specific loci, no consistent change in 
DNMT expression levels could be detected (Borghese et al. 2010; Dyson et al. 2015; van 
Kaam et al. 2011; Wu et al. 2007). This goes in line with the wide spectrum of findings 
even across the normal menstrual cycle. At the same time, since the methylation changes 
involve an almost equal distribution of hypo- and hypermethylated sites, substantial 
global differences in DNMT or TET levels would not be expected. 
As far as I am aware there are no studies on putative changes in 5hmC level or 
distribution in endometriosis samples that have been conducted so far. This will be an 
interesting avenue to investigate, alongside the screening for 5mC changes, to examine if 
endometriosis may result in alterations in these epigenetic modifications in eutopic 
tissue. 
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1.4 Project Aims 
 
The main aim of the project was to gain a deeper understanding of the epigenomic 
profile of the endometrium during the secretory phase, i.e. during the critical time 
window for a successful implantation, in eutopic endometrium of women with 
endometriosis and endometrium from controls. To achieve this, I took the approach of 
assessing multiple epigenetic modifications in the same tissue samples, as this will 
enable me to gain an integrated view of any potential epigenetic changes that may be 
connected to the disease. Since many of the epigenetic modifications act in an 
interconnected manner, this approach is more powerful than the investigation of any of 
these modifications in isolation. The approach was aimed to establish directly 
comparable epigenomic profiles and to analyse them for alterations that correlate with 
disease state. 
My specific project aims are to: 
 Establish genome-wide profiles for the histone modifications H3K4me3, 
H3K9me3 and H3K27me3, as well as for DNA methylation and 
hydroxymethylation, from secretory phase-timed endometrial biopsies of control 
patients and patients with endometriosis. 
 Determine if any of these profiles are altered in the eutopic endometrium of 
women with endometriosis. 
 Determine if any individual modification, or the combinatorial status of different 
modifications at multiple sites, may be used to establish an epigenetic biomarker 
panel for discriminating endometriosis that hence may aid the diagnosis of 
endometriosis in the future. 
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Figure 2.1 Experimental Schematic of the workflow. A, Endometrium biopsy and organoid 
experimental design schematic for global epigenetic profiling. 
	
ØmeDIP-seq: Immunoprecipitation of 5-methylcytosine (5mC) 
followed by sequencing
ØhmeDIP- seq: Immunoprecipitation of 5-
hydroxymethylcytosine (5hmC) followed by sequencing
ØRNA-seq: Establishment of global expression profile
ØMS: Mass Spectrometry of 5mC and 5hmC
ØTMOT: TrueMethyl® On Target sequencing of 5mC and 
5hmC
Ø Input DNA sequencing as control 
Ø H3K4me3 ChIP-seq: Chromatin immunoprecipitation of 
H3K4me3 followed by sequencing  
Ø H3K27me3 ChIP-seq: Chromatin immunoprecipitation of 
H3K27me3 followed by sequencing  
Ø H3K9me3 ChIP-seq: Chromatin immunoprecipitation of 
H3K9me3 followed by sequencing  
Ø IgG ChIP: Chromatin immunoprecipitation of IgG followed 
by qPCR as control
Ø IF for 5mC and 5hmC 
Ø IF for H3K4me3 and H3K27me3
Ø IF for NNMT and E-Cadherin
Ø LCM-HMCP: Laser Capture Microdissection of glandular 
epithelial cells followed by Hydroxymethylation Capture 
Pulldown
Ø LCM-MS: Laser Capture Microdissection of glandular 
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Table 2.1 Human Endometrial Tissue Information: Patient information was provided by Warwick Medical School. Abbreviations: (R)IVF – 
(Recurrent) In vitro Fertilisation, MC – Miscarriage, PCOS – Polycystic ovary syndrome, ICSI – Intracytoplasmic Sperm Injection, (R)IUI – 
(Recurrent) Intrauterine Insemination, PUL – Pregnancy of Unknown Location. Colour Key: green – sample used for analysis, red – sample removed 
due to availability (n/a) or technical reasons (No). Unpaired two-way t-tests were non-significant between the Control and the Endometriosis groups: 















31 21.9 LH+8 1x IVF(MC), 1x ICSI, PCOS n/a Receptive Yes Yes Yes Yes Yes n/a n/a n/a n/a Yes
31 n/a LH+9 Fibroid myomectomy n/a Receptive Yes Yes Yes Yes No No Yes Yes Yes Yes
38 21 LH+6 RIVF n/a Non-receptive Yes Yes No No No Yes Yes Yes Yes Yes
38 23.3 LH+9 RIVF n/a Receptive Yes Yes Yes Yes Yes Yes Yes n/a n/a Yes
37 n/a LH+9 1x IVF failure n/a Receptive Yes No Yes No No Yes Yes n/a n/a No
33 23 LH+7 1x IVF failure n/a Receptive Yes No Yes Yes Yes Yes Yes No Yes No
32 n/a LH+7 1x ICSI(MC) n/a Non-receptive Yes Yes Yes Yes No Yes Yes Yes Yes Yes
32 20 LH+8 2x IVF failure n/a Non-receptive Yes Yes Yes Yes Yes Yes Yes n/a n/a Yes
38 20 LH+8 RIVF n/a Non-receptive Yes Yes Yes No Yes Yes Yes Yes Yes Yes
37 23 LH+9
2x IVF: 1x biochemical loss, 
1x no transfer; male factor n/a Receptive Yes Yes Yes Yes Yes Yes No Yes Yes Yes
34 21.3 LH+7 Dysmenorrhea. 3x IUI, 2x 
IVF
Severe Receptive Yes Yes No No No Yes Yes n/a n/a Yes
28 18 LH+8 Mild Receptive Yes Yes Yes Yes Yes n/a n/a n/a n/a Yes
39 n/a LH+8 Adenomyosis. RIVF Severe Receptive Yes Yes Yes Yes No Yes Yes n/a n/a Yes
34 25 LH+9 Dysmenorrhea. RIUI Mild Receptive Yes Yes Yes Yes Yes No Yes No Yes Yes
33 22 LH+9 RIVF Severe Receptive Yes Yes No No No Yes Yes Yes Yes Yes
39 26 LH+6 Dysmenorrhea, Dermoid 
oopherectomy. 5x RIVF
Moderate Non-receptive Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
39 38 LH+6 RIVF Severe Non-receptive Yes Yes Yes Yes No No Yes Yes Yes Yes
31 n/a LH+6 Dysmenorrhea. RIVF Severe Non-receptive Yes Yes Yes No No Yes Yes Yes Yes Yes
38 26 LH+8 RIVF, 2x PUL Severe Receptive Yes Yes Yes No Yes Yes Yes n/a n/a Yes
39 31 LH+8 RIVF Severe Receptive No Yes Yes No Yes Yes Yes Yes Yes Yes
Laser Capture 




























Sample Information GW analysis Immunofluorescence
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Table 2.2 List of primers used. A table of primers used for quality control of enrichment 
analysis for ChIPs as well as primers for RT-qPCR. 
Gene Direction Sequence Purpose 
GNAS F TCCCCGTCGAGAATGATGGC meDIP QC 
  R GGGCTCCAGCTTCCCTGAAT   
OR4F3 F ATGTGGCCCTATGTAAGCCCC meDIP QC 
  R TGCCAGTTGGAACAGGGAGT   
MUC6 F GTTGGTGACTGGAGAGGTGG hmeDIP QC 
  R CGGTCCACTTCTCTCACCAC   
OCLN F ACTTCAGGCAGCCTCGTTAC hmeDIP QC 
  R CCGCCAGTTGTGTAGTCTGT   
GAPDH F CAGGCTGGATGGAATGAAAG ChIP QC 
  R AAAGGCACTCCTGGAAACCT   
NANOG F GAGATGGGCACGGAGTAGTCTT ChIP QC 
  R TGTCTATCCCTCCTCCCAGGTA   
NDN F CCACTTCTTGTAGCTGCCGA ChIP QC 
  R TGTGGTACGTGCTGGTCAAG   
GAPDH F CGCTGAGTACGTCGTGGAGT RT-qPCR 
  R GGGCAGAGATGATGACCCTTT   
PAEP F GCTGCTCGATACTGACTACGA RT-qPCR 
  R AAGCCCTGATGAATCCCTGC   
GPX3 F GGTCTGGTCATTCTGGGCTT RT-qPCR 
  R TAGGGACAAAGCCTCCACCT   
NNMT F CAGAGGCCTTTGACTGGTCC RT-qPCR 
  R GCTGGCTCTGAGTCACATCA   
GP2 F AAGTCCGCAGTGAAGTACCG RT-qPCR 
  R CCATTCATGACACCGGGAGA   
KCNG1 F GTCAACCTCTCCGTCAGCAC RT-qPCR 
  R CGATGAAGACGTTGTGGCAC   
GJB6 F ACACTGGCAGTCGTTGGAAA RT-qPCR 
  R CGATGCTGGTGGAGTGTTTG   
FAM20C F TCACACGGGACAAGAAGCTC RT-qPCR 
  R CTCGATCTGGTCTGGCTTCC   
TNC F ATCAGTCACCGGTTACCTGC RT-qPCR 
  R CTGTGTAGTGGGTGGATGGG   
PLA2G4E F GATGCCTGGAACCTGTCACA RT-qPCR 
  R GGGATTTCAGGCAGGATCGG   
SYT2 F ATGAACACAGTGGACCTCGG RT-qPCR 
  R ATGCAGACAGTGAGCTTCCC   
DNMT1 F GGCTATCAGTGCACCTTCGG RT-qPCR 
  R GGGAACAGAGGGAGCTTCTC   
DNMT3A F GCCAAAGAAGTGTCAGCTGC RT-qPCR 
  R CCATGCTCCAGACACTCCTG   
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DNMT3B F TGCCATCAAAGTTTCTGCTGC RT-qPCR 
  R CAGTCCTGCAGCTCGAGTTT   
DNMT3L F CTGACCCGGGACAACTGAAG RT-qPCR 
  R CGCCGTACACAAGATCGAAG   
TET1 F CTGCTTGCCTGGACTTCTGT RT-qPCR 
  R GGAATAACACCCAAAGAGCGG   
TET2 F CATGCCCACAGAGACTTGCA RT-qPCR 
  R TGAAGCTGCTCATCCTCAGG   
TET3 F CGACACCCTCCGGAAGTATG RT-qPCR 
  R ACCAAAGGAGAAGGAGGCAC   
HMBS F AGGAGTTCAGTGCCATCATCCT RT-qPCR 

















 High-throughput sequencing of Methylated or Hydroxymethylated 2.5
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 Immunofluorescence (IF) staining 2.7
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 Bioinformatic analysis 2.13
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Characterising the precise receptivity 
state of the endometrium 
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3.2 Genome-wide expression profiles reveal the precise receptivity stage, 
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Figure 3.1 RNA-sequencing quality control for endometrial samples. A, An example of 
quality control checks on raw sequencing data, per base sequencing quality score. B, Mapped 
data quality control of the percentage of reads that fall into genes, exons, ribosomal 
ribonucleic acid (rRNA) and mitochondrial DNA (MT). Also showing the percentage of 
genes with reads, the number of reads in each sample compared to the largest data set and the 
percentage of reads on the sense strand. C, Cumulative distribution graph of RNA-sequencing 













CA Cumulative Distribution GraphFASTQC Sequencing quality
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Figure 3.2 Whole tissue transcriptional profiling 
of endometrial biopsies. A, Neighbour joining tree, 
with distances calculated by Pearson correlation, 
showing the degree of relatedness between the 
endometrial biopsies. Ctrl = Control, Endo = 
Endometriosis. Marron box = Non-receptive, Blue 
box = Receptive B, Scatterplot of RNA-seq data 
comparing receptive and non-receptive endometrial 
biopsies, with each dot representing a gene. Blue dots 
correspond to Endometrial Receptivity Array (ERA) 
positive genes whilst the magenta dots to ERA 
negative genes. C, The non-receptive and receptive 
samples merged and plotted against the ERA genes in 
a heatmap.  
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Positive regulation of synapse assembly
Non-Receptive Control
Figure 3.3 The receptivity expression 
signature of non-receptive and 
receptive endometrium. A, Scatterplot 
of RNA-seq data comparing receptive 
and non-receptive control endometrial 
biopsies, with each dot representing a 
gene. Blue dots correspond to genes 
that are up-regulated whilst magenta 
dots depict down-regulated genes in 
receptive control endometrium. 
Differential expression was compiled 
through a combination of DESeq2 and 
EdgeR analyses with a minimum log2 
difference of 2.0. B, Independent 
validation of differentially expressed 
genes between the non-receptive and 
receptive state by RT-qPCR. Relative 
expression was normalised against 
housekeeping gene, GAPDH. Data is 
mean +/- SEM. Statistical analysis is by 
two-way ANOVA followed by Tukey’s 
post-hoc test on log transformed data. 
*** p<0.001, **** p<0.0001. C, Gene 
Ontology biological process treemap of 
enriched genes identified in 3.3A using 
GOrilla and REVIGO tools with 
background list of genes with >20reads 
and Bonferroni p<0.05 applied. 
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3.3 Virtual deconvolution of cell type composition of endometrial tissue biopsies 








Figure 3.4 Cell type composition of endometrial tissue with virtual deconvolution. A, 
Example image of DAPI-stained endometrial tissue to highlight nuclear staining. The dotted 
lines demarcate glandular epithelium. S = stromal cells, GE = glandular epithelium. B, 
Scatterplot of RNA-seq data comparing stromal and epithelial cell organoids, with each dot 
representing a gene. Green dots correspond to genes that are only expressed in epithelial cell 
organoids, whilst red dots show genes expressed only in stromal cell organoids. C, Virtual 
deconvolution of approximate percentage of epithelial and stromal cells contributing to whole 
tissue +/- SEM. Two-way ANOVA followed by Tukey’s post-hoc test showed no significant 
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Figure 3.5 The importance of epithelial cells in the transition to receptivity. A, Heatmap 
of epithelial cell signature genes in whole tissue samples discriminates receptivity states. 
These whole tissue samples are grouped according to receptivity. B, Virtual deconvolution of 
approximate percentage of stromal cells, non-receptive and receptive epithelial cells 
contributing to whole tissue. Mean +/- SEM plotted. Two-way ANOVA followed by Tukey’s 
post-hoc test showed significant difference of non-receptive (p<0.0001) and receptive 
(p<0.0001) epithelial cell signature between the non-receptive and receptive state. C, Venn 
diagram showing genes that are differentially regulated between the non-receptive and 
receptive state as established in the whole tissue expression analysis (ERT, orange). This is 
overlapped with data from Salker et al. of RNA-seq data from laser-capture microdissected 
epithelial cells at LH+5 and LH+8, filtered to have an expression fold change of at least 4.0 
















% Non-Receptive Epithelial% Receptive Epithelial % Stromal
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3.4 Characterisation of histone modification dynamics 
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Figure 3.6 Distribution of H3K4me3 and H3K27me3 in endometrial tissue with regards 
to receptivity. A, Immunofluorescence staining of endometrial tissue in the non-receptive and 
receptive state for H3K4me3 (green) and H3K27me3 (red). DAPI (blue) was used as a 
nuclear counter-stain. Scale bar = 100µm or 20µm in zoomed merged images B and C, 
Epithelial: Stromal cell ratio of mean intensity units within each immunofluorescence image. 
Two-way ANOVA followed by Tukey’s post-hoc test showed p = 0.0731 and 0.2569 for 
H3K4me3 and H3K27me3, respectively. Box whisker plot with minimum, median and 
maximum values plotted. All conditions had a minimum of 3 samples with 3 images each. NR 
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Figure 3.7 Quality control of endometrial tissue histone-ChIP. A, An example ChIP-qPCR 
of GAPDH (housekeeping gene), NANOG (repressed developmental gene) and NDN 
(imprinted gene) for histone enrichment quality control. Data are normalised to Input. B, C 
and D, Cumulative distribution graphs of Input and histone ChIP-seq data, using 5kb tiling 
probes across genome spaced 2.5kb apart. Data are corrected to largest dataset, log2 
transformed and enrichment normalised to 20th and 90th percentile where applicable. Grey box 
illustrates inputs flat distribution. Violet boxes illustrate ChIPs dynamic distribution. E, 2Mb 
view of input and histone-ChIP-sequencing data, 2kb probes across genome every 1kb 
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Figure 3.8 H3K4me3 correlates with expression at TSSs. A, H3K4me3 enrichment is 
aligned across transcription start sites +/- 5kb on either side, for non-receptive and receptive 
A
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samples. These have been further subdivided according to the level of gene expression 
established in the RNA-seq. High expression was defined as read count values above median 
RPM, low expression as between median RPM and 0 RPM, no expression as below 0 RPM. 
	




























- Chapter III - 
- Natasha Poppy Morgan - 81	
Figure 3.9 Bivalency is key during the transition to a receptive state. A, chromstaR 
analysis of peak frequency in non-receptive (maroon) and receptive (blue) state. Chi-square 
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H3K27me3-only and H3K4me3 & H3K37me3. B, Slankey diagram of the chromatin state 
destination of bivalently marked regions that resolve to another state during the transition 
from non-receptive to receptive state. C, Enrichment of H3K9me3 at various repeat elements. 
Analysis was conducted, by the Babraham Bioinformatics department. Two-way ANOVA 
shows no significant differences between the receptive and non-receptive samples at any of 
the elements analysed. D, Expression analysis of genes that are bivalently marked in the non-
receptive state and resolve to H3K4me3-only in the receptive state. Wilcoxon test, 
****p<0.0001. E, Gene Ontology analysis of genes that are bivalently marked in the non-
receptive state and resolve to H3K4me3-only in the receptive state. This was carried out using 
DAVID bioinformatics tool with a background list of all bivalent genes in the non-receptive 
state. Bonferroni correction applied, p<0.05. F, Motif enrichment analysis of the regions that 
resolved to H3K4me3-only, carried out using AME tool in MEME Suite, showing enrichment 
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Figure 3.10 Bivalency dynamics at specific loci. A and B, Wiggle plots of gene expression 
and chromatin enrichment data at the SOD2 and ELF3 gene loci, respectively. RNA-seq 
(RPM log2), H3K4me3 and H3K27me3 enrichment of ChIP-seq data (normalised to largest 
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dataset) are shown in non-receptive and receptive state. Regions that resolve their bivalency 
to H3K4me3-only in the receptive state are denoted by black boxes, with greyed out areas 
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Hydroxymethylation is a major 
hallmark of receptivity in endometrial 
tissue 
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4.2 Identification of cell-type specific 5hmC levels between the non-receptive 
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Figure 4.1 5mC and 5hmC mass 
spectrometry of the endometrium. A and 
B, Mass spectrometry of 5mC and 5hmC of 
endometrial biopsies in the non-receptive 
and receptive state. Two-way ANOVA 
followed by Tukey’s post-hoc test showed no 
significant difference, p = 0.8801 and 0.3723 
respectfully. NR = non-receptive (n=7), R = 
receptive (n=11) C, Mass spectrometry of 
mouse and human tissue (Globisch et al., 
2010; Godderis et al., 2015), including my 
endometrial samples, for 5mC and 5hmC. 
Mean +/- SD plotted. D, The ratio of 
5hmC:5mC in mouse and human tissue 
(Globisch et al., 2010; Godderis et al., 2015) 
along with endometrium. Mean plotted.  
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Figure 4.2 5hmC distribution in non-receptive and receptive endometrium. A, 
Immunofluorescence staining of endometrial tissue in the non-receptive and receptive state 
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white arrows. Scale bar = 100µm B, The epithelial: stromal cell ratio of the mean 
fluorescence intensity units for 5hmC (individual data points and mean +/- SD plotted). Non-
receptive samples: n=6, at least 2 images per biological replicate; Receptive samples: n=8, at 
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Figure 4.3 Laser capture microdissection coupled with mass spectrometry. A, Images 
from section used for laser capture microdissection (LCM) of epithelial cell in the 
endometrium in the non-receptive and receptive state. Left image: Prior to LCM. Middle 
image: After LCM, epithelial cells laser-cut out. Right image: Epithelial cells catapulted into 
the lid of a 0.5ml Eppendorf tube. B and C, Mass spectrometry of LCM epithelial cells in the 
NR (non-receptive) and R (receptive) state to determine absolute quantities of 5hmC and 
5mC. n= 6 for both non-receptive and receptive samples. Two-way ANOVA followed by 
Tukey’s post-hoc test showed p = 0.1610 and 0.1744 for 5hmC and 5mC, respectively. 
Mean+/-SD plotted. 
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Figure 4.4 DNA hydroxymethylation analysis of laser microdissected endometrial 
epithelial cells. A, The relative 5hmC enrichment of different genomic features. Features 
were determined using GRCh38 in SeqMonk with enrichment calculated by: log2% reads / % 
genome. Unpaired two-tailed t-test was performed for each feature, no significant differences 
were observed. B, Neighbour joining tree, with distances calculated by Pearson correlation, 
showing the degree of relatedness between epithelial cells in either the non-receptive or 
receptive state. C and D, LCM-HMCP read count at promoters (-1kb to +100bp around TSS) 
of genes specific for the non-receptive (C) or receptive (D) state, as determined by my 
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Figure 4.5 5hmC is enriched at promoters of specific genes. A and B, Wiggle plots for 
PAEP (A) and NNMT (B). RNA-seq tracks of whole tissue (RPM log2-transformed) and 
LCM-HMCP of epithelial cells (log2-transformed) for non-receptive and receptive states. 
Promoters (-1kb to +100bp around TSS) are highlighted by black box, with greyed out area 
underneath. mRNA and coding sequence (CDS) displayed. Tracks are merged results of non-
receptive n=3 (RNA-seq or corresponding LCM 5hmC), receptive n=2 (RNA-seq or 
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Figure 4.6 5hmC at bivalently marked promoters. A, LCM-HMCP enrichment at all 
promoters in non-receptive and receptive epithelial cells (grey boxes), bivalent promoters in 
non-receptive epithelial cells (maroon box) and bivalent promoters that resolved to 
H3K4me3-only in receptive epithelial cells (blue box). Middle line is the median, boxes edges 
are the 25th and 75th percentile, whiskers = median +/- the interquartile (25-75%) range x2, 
dots indicate outliers of this range. B, LCM-HMCP epithelial trend plot +/- 5kb of TSS. 
Dotted lines are promoters that remained bivalent in the receptive state. Solid lines are 
promoters that resolved to H3K4me3-only in the receptive state. Non-receptive= maroon, 
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Figure 4.7 DNA methylation and hydroxymethylation modifiers. A, RNA-seq expression 
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TET1, TET2 and TET3. DESeq2 and EdgeR statistical tests with Benjamini-Hochberg 
correction applied showed no significant differences. Plots depict mean +/- SEM. NR = non-
receptive state (n=4), R= receptive state (n=6) B, RNA-seq data (TPM log2) of isolated 
epithelial cells at LH+5 (n= 3) and LH+8 (n= 3) (Salker et al. 2017) of DNMT1, DNMT3A, 
DNMT3B, DNMT3L, TET1, TET2 and TET3. DESeq2 with Benjamini-Hochberg correction 
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Figure 4.8 NNMT expression in the endometrium. A, The expression of NNMT in whole 
tissue endometrium in the non-receptive and receptive state. RNA-seq data analysed with 
DESeq2 and Benjamini-Hochberg correction applied. **** p< 0.0001. NR= non-receptive 
(n=4), R= receptive (n=6). B, NNMT expression in isolated epithelial cells at LH+5 (n=3) and 
LH+8 (n=3) of the endometrial cycle (Salker et al. 2017). RNA-seq data analysed with 
DESeq2 and Benjamini-Hochberg correction applied **** p< 0.0001. C, Wiggle plot of 
RNA-seq data from epithelial (n=4) and stromal cell (n=4) organoids across the NNMT 
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Figure 4.9 NNMT. A, NNMT protein structure with methyltransferase site (orange) and S-
adenosylmethionine binding sites (grey) marked. B, Hypothesised mechanism of NNMT 
function within epithelial cells in the endometrium. A potential consequence of the profound 
up-regulation of NNMT in the receptive phase may be a decrease in 5mC and a relative 
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DAPI NNMT ECadherin Merged
Figure 4.10 NNMT protein levels in 
endometrium.               
A, Immunofluorescence images of NNMT in 
non-receptive and receptive endometrium. 
DAPI (blue), NNMT (green), E-Cadherin 
(red). E-Cadherin denotes epithelial cells. Scale 
bar = 100µm B, Calculation of the epithelial: 
stromal cell ratios of mean intensity units 
within each image. NR (n=4 with 2-3 images 
per a biological replicate), R (n=4 with 2-3 
images per a biological replicate). Mann-
Whitney two-tailed test **p = 0.0086. 
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Figure 4.11 Endogenous NNMT expression in HEC1A cells and proof of NNMT over-
expression upon transfection. A, RT-qPCR of non-receptive genes, KCNG1 and GJB6, 
receptive genes, PAEP and NNMT (black bar), genes involved in the deposition and removal 
of 5mC and its derivatives, DNMT1, DNMT3A, DNMT3B, DNMT3L, TET1, TET2 and TET3 
and housekeeping gene HMBS in HEC1A cells. Normalised to GAPDH.        
B, Immunofluorescence images of HEC1A cells transfected with a FLAG-tagged NNMT 
expression construct. DAPI (blue), NNMT or FLAG (green). C, Experimental design of 
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Figure 4.12 5mC and 5hmC in HEC1A cells over-expressing NNMT. A, The mean 
intensity units of 5mC in FLAG-Low (n=1236) and FLAG-High (n=332) HEC1A cells. 
Mann-Whitney test p=0.8541. B, The mean intensity units of 5hmC in FLAG-Low (n=687) 
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Figure 4.13 H3K4me3 and H3K27me3 in HEC1A cells OE NNMT.        
A, Immunofluorescence images of HEC1A cells transfected with a FLAG-tagged NNMT 
expression construct. DAPI (blue), FLAG (red), H3K4me3 or H3K27me3 (green). B, Mean 
intensity units of H3K4me3 in FLAG-Low (n=1714) and FLAG-High (n=373) HEC1A cells. 
Mann-Whitney test **** p<0.0001. C, Mean intensity units of H3K27me3 in FLAG-Low 
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Figure 5.1 Differential expression associated with endometriosis. A, Scatterplot comparing 
RNA-seq data from receptive controls with receptive endometriosis samples. DESeq2 and 
EdgeR analyses showed no significant differences. B, Scatterplot comparing non-receptive 
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multiple testing correction applied. DESeq2 p<0.05= blue, EdgeR p<0.05 = green, DESeq2 
and EdgeR = yellow. C, RT-qPCR of genes that were differentially expressed between 
control and endometriosis samples in the non-receptive state. Data was log2-transformed prior 
to statistical analysis. Unpaired two-tailed t-test was performed. ***p<0.001, *p<0.05. Mean 
+/- SEM plotted. Receptive Control (n=6), Receptive Endometriosis (n=6), NRC= non-
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Figure 5.2 H3K4me3 and H3K27me3 immunofluorescence in endometrium.       
A, Immunofluorescence images of control and endometriosis samples in the non-receptive 
and receptive states. DAPI (blue) was used as nuclear counter-stain, H3K4me3 (green) and 
H3K27me3 (red). Scale bar = 100µm B and C, Analysis of the epithelial: stromal cell ratio of 
mean intensity units within each immunofluorescence image for H3K4me3 and H3K27me3. 
Two-way ANOVA followed by Tukey’s post-hoc test showed no significant differences. 
NRC= non-receptive control, NRE= non-receptive endometriosis, RC= receptive control, 
RE= receptive endometriosis. All conditions had a minimum of 3 biological replicates with 3 
images each. Box whisker plot depicting the box as 25th percentile, medium and 75th 
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Figure 5.3 Histone methylation MACS2 peak profiles. A, B, C, D, E and F, Scatterplots of 
H3K4me3 (A, B), H3K9me3 (C, D) and H3K27me3 (E, F) with controls compared to 
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endometriosis samples in both non-receptive and receptive state. Corrected to largest dataset, 
log2-transformed and enrichment-normalised to the 20th and 90th percentile where applicable. 
DESeq2 and EdgeR statistics applied with no significant differences for H3K4me3 (A, B), 
H3K9me3 (C, D) or H3K27me3 in the non-receptive state (E). Significant statistical 
differences highlighted for H3K27me3 in the receptive state (F), DESeq2 = blue, EdgeR = 












Table 5.1 Genomic regions and nearby genes associated with differentially enriched 
H3K27me3 peaks between control and endometriosis samples in the receptive state. 
Corrected DESeq2 and EdgeR p values, log2-fold change: positive values indicate enrichment 
in endometriosis, negative values indicate enrichment in controls. 
Gene Full Name Chr Start End
DESeq2        
P-value

















null n/a 11 133831336 133832961 0.024 0.011 1.628
RP11-
271M24.2












No description X 137022230 137025182
0.049
-0.945
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Figure 5.4 Differential H3K27me3 enrichment at TMEM176A/B. A, Wiggle plot across 
the TMEM176A/B locus. RNA-seq and H3K27me3 tracks for control (n=4) and endometriosis 
(n=2) samples in the receptive state. MACS2 peak of differential H3K27me3 enrichment 
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Figure 5.5 H3K9me3 repetitive 
analysis. A, H3K9me3 analysis 
of repetitive regions. Two-way 
ANOVA followed by Tukey’s 
post-hoc test conducted revealed 
no significant differences. Mean 
+/- SD. NRC= non-receptive 
control (n=2), NRE= non-
receptive endometriosis (n=2), 
RC= receptive control (n=5), 
RE= receptive endometriosis 
(n=3). 
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5.4 DNA hydroxymethylation dynamics are altered in endometriosis 
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Figure 5.6 5mC and 5hmC levels in control and endometriosis samples. A and B, Mass 
spectrometry of 5mC (A) and 5hmC (B) of endometrial biopsies from control and 
endometriosis patients, plotted according to receptivity and disease state. C and D, Analysis 
of immunofluorescence stainings of 5mC (C) and 5hmC (D), displayed as the epithelial: 
stromal cell ratio of mean intensity units in the non-receptive and receptive state. Two-way 
ANOVA followed by Tukey’s post-hoc test showed no significant differences. NRC= non-
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Figure 5.7 5mC and 5hmC correlation between control and endometriosis samples. A 
and B, Scatterplots of meDIP-seq data analysed with 2kb running window probes spaced 1kb 
apart, comparing controls and endometriosis samples in the non-receptive (A) and receptive 
(B) state. C and D, Scatterplots of hmeDIP-seq data using the same type of analysis in the 
non-receptive (C) and receptive (D) state. Non-receptive control (n=4), Non-receptive 
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Figure 5.8 5mC and 5hmC 
at CGIs and repetitive 
regions. A, Gene expression 
(RPM Log2-transformed 
RNA-seq data) of genes 
associated with either all CGIs 
(grey), with CGIs that have 
low 5mC and high 5hmC, or 
with CGIs with high 5mC and 
low 5hmC split by receptivity 
and disease state. Middle line 
is the median, box edges are 
the 25th and 75th percentile, 
whiskers are the median +/- 
the interquartile (25-75%) 
range x2. B and C, 5mC (B) 
and 5hmC (C) analysis of 
repetitive regions. Two-way 
ANOVA followed by Tukey’s 
post-hoc test revealed no 
significant differences. Mean 
+/- SD. NRC= Non-receptive 
control (n=4), NRE= Non-
receptive endometriosis (n=3), 
RC= Receptive control (n=4), 
RE= Receptive endometriosis 
(n=7). 
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Figure 5.9 5mC and 5hmC Feature 
Distribution. A, B and C, The 
relative enrichment of different 
genomic features. Features were 
determined using GRCh38 in 
SeqMonk with enrichment calculated 
by: log2% reads / % genome for 5mC 
(A), 5hmC (B) and the ratio of 
5hmC:5mC (C). Mean +/- SD. Two-
way ANOVA followed by Tukey’s 
post-hoc test revealed a significant 
interaction marked by asterisks, with 
the dotted arcs visualising the 
enrichment pattern in the different 
sample groups. **p<0.01, *p<0.05. 
NRC= non-receptive control (n=4), 
NRE = non-receptive endometriosis 
(n=3), RC = receptive controls 
(RC=4), RE = receptive 
endometriosis (n=7). 
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5.4.2 Locus-specific changes in DNA methylation and hydroxymethylation reveal 











- Epigenetic changes associated with endometriosis - 
- Doctor of Philosophy - University of Cambridge - 2019 - 148	
Figure 5.10 Differentially methylated and hydroxymethylated regions in endometriosis. 
A and B, Scatterplot of meDIP-seq data analysed with 2kb running window probes spaced 
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receptive (B) state. Differentially methylated probes are highlighted. C and D, Scatterplot of 
hmeDIP-seq data analysed in the same way in the non-receptive (C) and receptive (D) state, 
again with differentially hydroxymethylated probes highlighted. Differential enrichment was 
determined by unpaired two-tailed t-test and a log2-fold change of at least 2. E, Gene 
Ontology analysis of genes within 2kb of the top 500 differentially marked regions. This was 










































Figure 5.11 Heatmap of 
DMRs and DhMRs 
associated with Hippo 
signalling genes. A, 
Heatmap of 2kb probes 
differentially enriched for 
5mC or 5hmC that are 
associated with the genes in 
the Hippo signalling 
pathway. Samples pooled for 
each group: Non-receptive 
control (n=4), Non-receptive 
endometriosis (n=3), 
Receptive control (n=4), 
Receptive endometriosis 
(n=7). 
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Figure 5.12 Differential 5mC and 5hmC associated with the Hippo Pathway. A, Diagram 
of the Hippo pathway (hsa04390) from KEGG (https://www.genome.jp/dbget-
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enriched epigenetic marks colour-coded as follows: DMRs (orange), DhMRs (yellow), and 
DMRs and DhMRs (orange and yellow). B, Enrichment of Hippo signalling genes associated 
with 2kb regions that were differentially marked by 5mC or 5hmC. Chi-square test with Yates 
correction applied *p<0.05. C, The overlap of differentially marked 2kb regions with Hippo 
signalling genes, defined by KEGG. 
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Figure 5.13 Candidate regions identified by the meDIP- and hmeDIP-seq analysis 
selected for independent validation. A, Distribution of regions selected for validation across 
the genome. FOXO1 data = GSM1703607, PGR data = GSM1703567, Previously Identified 
DMRs or CpGs = GSE90060. B and C, Principal component analysis (PCA) plots of the 
meDIP (B) or hmeDIP (C) regions selected for validation. Each plot is highlighted for either 
the disease state or receptivity state. Solid lines denote control (dark grey) or endometriosis 
(light grey). Dotted lines denote receptive state (dark grey) or non-receptive state (light grey). 
Non-receptive control (n=4), Non-receptive endometriosis (n=3), Receptive control (n=4), 
Receptive endometriosis (n=7). 
A
B






FOXO1 binding sites 16 29
PGR binding sites 11 9
Previously Identified DMRs or CpGs 6 17
Total 236 175
411
Receptive ControlNon-Receptive Control Non-Receptive Endometriosis Receptive Endometriosis
Control Endometriosis Receptive Non-Receptive
C
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Figure 5.14 OxBS and BS sequencing. A, The base calling after oxBS or BS conversion and 
subsequent sequencing. B, Schematic of the sequencing read out and the establishment of 
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Figure 5.15 TMOT validation of selected candidate regions. A, The table shows the 
number of CpGs that are present in the regions that are to be validated (in column two). The 
number of CpGs that have a q value <0.01 (confidence in the methylation call across samples) 
are shown (in column three), followed (in column four) by the number of CpGs that validated 
and (in column five) the percentage of CpGs that validated. B, C, D, and E, Manhattan plots 
of the CpGs that had q values <0.01 with the y-axis showing the % of differential methylation 
between conditions and the size of the dot positively correlating with the significance of the 
differential methylation. In these graphs, each vertical line reflects one particular gene locus 
that may contain multiple CpG sites. 5mC or 5hmC “validation” is considered for each CpG. 



























































































































































































































































































































































































































































C vs E 243 89 80 90%
NRC vs RC 1000 93 55 59%
NRC vs NRE 12 3 2 67%
RC vs RE 2014 36 27 75%
5hmC
C vs E 5 5 2 40%
NRC vs RC 984 205 91 44%
NRC vs NRE 984 137 96 70%
RC vs RE 2788 377 158 42%
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Figure 5.15 TMOT validation continued. F, G, H and I, Manhattan plots of the CpGs for 
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Figure 5.16 CpGs that validated for differential 5mC and 5hmC enrichment. A and B, 
PCA plots of the validated individual 5mC CpGs (A) or validated individual 5hmC CpGs (B) 
from the TMOT validation analysis. Each plot is highlighted for either the disease state or 
receptivity state. Solid lines denote control (dark grey) or endometriosis (light grey). Dotted 
lines denote receptive state (dark grey) or non-receptive state (light grey). Non-receptive 
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6.1 Receptivity and its foremost importance 
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Figure 6.1 Hypothetical diagram of the role of bivalency and 5hmC in the 
Endometrium. As the endometrium progresses through the menstrual cycle it receives 
multiple external and internal signals. These signals may result in the addition of 5hmC at 
bivalent regions which in turn demarcates these loci towards resolution to H3K4me3-only and 
the induction of gene expression. This process could continue as the endometrium receives 
additional signals resulting in remaining bivalent regions gaining 5hmC and resolving to 
H3K4me3. Since endometrial epithelial cells exhibit the most dramatic dynamics in 5hmC 
levels, this regulation may specifically pertain to this cell type. 
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6.2 The dynamic alterations of the epigenetic profile in endometriosis 
































- Discussion - 



































- Chapter VI - 

































- Discussion - 































- Chapter VI - 
- Natasha Poppy Morgan - 185	

































- Discussion - 








Figure 6.2 Hippo signalling pathway. The Hippo signalling pathway affects several cellular 
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Supplementary Figure 1 Component Gene Ontology analysis of the receptivity 
signature. A, Gene Ontology component treemap of enriched genes identified in Figure 3.3A 
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Supplementary Figure 2 Receptivity of the organoids. A and B, Scatterplot of RNA-seq 
data comparing epithelial organoids (A) or stromal organoids (B) with the receptivity state 
established using the corresponding endometrial whole tissue. Each dot represents a gene with 
blue dots corresponding to the positive genes and marron dots corresponding to the negative 
genes in the endometrial receptivity array. 
	
	
Supplementary Figure 3 KLF9 and FOXO1 Expression. A, RNA-seq expression levels 
(RPM log2) in whole endometrial tissue of KLF9 and FOXO1. Plots depict mean +/- SEM. 
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Supplementary Figure 4 Endometrial immunofluorescent images for 5mC, 5hmC and 
negative stainings. A, Immunofluorescence staining of endometrial tissue in the non-
receptive and receptive state with 5hmC (green), 5mC (red) and DAPI nuclear counterstain 
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Supplementary Figure 5 5hmC of LCM endometrial epithelial cells A, Cumulative 
distribution graph of Input and HMCP data, using 5kb tiling probes across genome spaced 
2.5kb apart. Data are corrected to largest dataset, log2 transformed. Grey box illustrates inputs 
flat distribution. Violet boxes illustrate HMCPs dynamic distribution. B, Neighbour joining 
tree, with distances calculated by Pearson correlation, showing the degree of relatedness 
between epithelial cells in either the non-receptive or receptive state at CpG Islands. 
	
Supplementary Figure 6 The expression of differentially methylated Hippo genes. A and 
B, Heatmap of the expression of hippo genes that were differentially methylated between 
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non-receptive control, NRE = non-receptive endometriosis, RC = receptive control, RE = 
receptive endometriosis.  
	
Supplementary Figure 7 The expression of differentially hydroxymethylated Hippo 
genes. A and B, Heatmap of the expression of hippo genes that were differentially 
hydroxymethylated between controls and endometriosis samples in the non-receptive (A) or 
receptive (B) state. NRC = non-receptive control, NRE = non-receptive endometriosis, RC = 
receptive control, RE = receptive endometriosis. 
NRC NRE RC REA B
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Supplementary Tables 
	
Supplementary Table 1 Endometrial Receptivity Transcriptome (ERT) genes. List of the genes in the ERT signature that was developed using 
non-receptive and receptive endometrial whole tissue samples. Genes marked as non-receptive are upregulated in the non-receptive state and genes 
marked receptive are upregulated in the receptive state. 
Gene Chr Start End Upregulated in: Description 
RBP7 1 9997216 10016020 non-receptive retinol binding protein 7, cellular  
MFAP2 1 16974502 16980835 non-receptive microfibrillar-associated protein 2  
ALPL 1 21509372 21578412 non-receptive alkaline phosphatase, liver/bone/kidney  
FNDC5 1 32862268 32872480 non-receptive fibronectin type III domain containing 5  
GJA4 1 34792998 34795747 non-receptive gap junction protein, alpha 4, 37kDa  
DAB1 1 56994778 57424057 non-receptive Dab, reelin signal transducer, homolog 1 (Drosophila)  
MCOLN3 1 85018082 85048470 non-receptive mucolipin 3  
NTNG1 1 107140007 107483458 non-receptive netrin G1  
PHGDH 1 119711887 119744215 non-receptive phosphoglycerate dehydrogenase  
ECM1 1 150508076 150513789 non-receptive extracellular matrix protein 1  
CRABP2 1 156699606 156705816 non-receptive cellular retinoic acid binding protein 2  
ATP1B1 1 169105697 169132722 non-receptive ATPase, Na+/K+ transporting, beta 1 polypeptide  
VASH2 1 212950520 212991585 non-receptive vasohibin 2  
GREM2 1 240489573 240612149 non-receptive gremlin 2, DAN family BMP antagonist  
RGS7 1 240775514 241357230 non-receptive regulator of G-protein signalling 7  
KMO 1 241532134 241595642 non-receptive kynurenine 3-monooxygenase (kynurenine 3- hydroxylase)  
NRXN1 2 49918505 51032536 non-receptive neurexin 1  
CTNNA2 2 79185231 80648861 non-receptive catenin (cadherin-associated protein), alpha 2  
PROM2 2 95274453 95291308 non-receptive prominin 2  
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NR4A2 2 156324432 156342348 non-receptive nuclear receptor subfamily 4, group A, member 2  
ERMN 2 157318625 157327713 non-receptive ermin, ERM-like protein  
B3GALT1 2 167868948 167874041 non-receptive UDP-Gal:betaGlcNAc beta 1,3- galactosyltransferase, polypeptide 1 
MAP2 2 209424058 209734118 non-receptive microtubule-associated protein 2  
LRRN1 3 3799437 3847703 non-receptive leucine rich repeat neuronal 1  
PFKFB4 3 48517684 48561172 non-receptive 6-phosphofructo-2-kinase/fructose-2,6- biphosphatase 4  
SEMA3G 3 52433053 52445085 non-receptive sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3G  
PRICKLE2-
AS1 
3 64067964 64103131 non-receptive PRICKLE2 antisense RNA 1  
ROBO2 3 75906695 77649964 non-receptive roundabout, axon guidance receptor, homolog 2 (Drosophila)  
STXBP5L 3 120908072 121424761 non-receptive syntaxin binding protein 5-like  
SLC15A2 3 121894089 121944102 non-receptive solute carrier family 15 (oligopeptide transporter), member 2  
PODXL2 3 127629181 127672809 non-receptive podocalyxin-like 2  
COL6A6 3 130560334 130678155 non-receptive collagen, type VI, alpha 6  
RAB6B 3 133824239 133895836 non-receptive RAB6B, member RAS oncogene family  
EPHB1 3 134615365 135260467 non-receptive EPH receptor B1  
VEPH1 3 157259742 157533619 non-receptive ventricular zone expressed PH domain- containing 1  
EPHB3 3 184561784 184582409 non-receptive EPH receptor B3  
FGF12 3 192139395 192767764 non-receptive fibroblast growth factor 12  
FGFR3 4 1793307 1808872 non-receptive fibroblast growth factor receptor 3  
PPP2R2C 4 6320578 6563600 non-receptive protein phosphatase 2, regulatory subunit B, gamma  
ERVMER34-1 4 52742552 52751640 non-receptive endogenous retrovirus group MER34, member 1  
RASL11B 4 52862290 52866835 non-receptive RAS-like, family 11, member B  
EPHA5 4 65319563 65670495 non-receptive EPH receptor A5  
FRAS1 4 78057570 78544269 non-receptive Fraser extracellular matrix complex subunit 1  
SCD5 4 82629539 82798857 non-receptive stearoyl-CoA desaturase 5  
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BMPR1B-AS1 4 94743800 94757533 non-receptive BMPR1B antisense RNA 1 (head to head)  
PCDH10 4 133149315 133194700 non-receptive protocadherin 10  
PABPC4L 4 134196333 134201748 non-receptive poly(A) binding protein, cytoplasmic 4-like  
LRAT 4 154626961 154753118 non-receptive lecithin retinol acyltransferase (phosphatidylcholine--retinol O-
acyltransferase)  
SORBS2 4 185585444 185956652 non-receptive sorbin and SH3 domain containing 2  
PLEKHG4B 5 140258 189970 non-receptive pleckstrin homology domain containing, family G (with RhoGef domain) 
member 4B  
ADAMTS16 5 5140330 5320304 non-receptive ADAM metallopeptidase with thrombospondin type 1 motif, 16  
HCN1 5 45259247 45696151 non-receptive hyperpolarization activated cyclic nucleotide-gated potassium channel1 
RGS7BP 5 64506299 64612312 non-receptive regulator of G-protein signaling 7 binding protein  
FAM169A 5 74777574 74866951 non-receptive family with sequence similarity 169, member A  
THBS4 5 80035348 80083287 non-receptive thrombospondin 4  
SLC27A6 5 128538013 129033642 non-receptive solute carrier family 27 (fatty acid transporter), member 6  
NRG2 5 139846779 140043299 non-receptive neuregulin 2  
SH3RF2 5 145936579 146081791 non-receptive SH3 domain containing ring finger 2  
SGCD 5 155870344 156767788 non-receptive sarcoglycan, delta (35kDa dystrophin- associated glycoprotein)  
KCNIP1 5 170353487 170736632 non-receptive Kv channel interacting protein 1  
MSX2 5 174724533 174730893 non-receptive msh homeobox 2  
NEDD9 6 11183298 11382348 non-receptive neural precursor cell expressed, developmentally down-regulated 9 
HLA-DOB 6 32812763 32817048 non-receptive major histocompatibility complex, class II, DO beta  
SPDEF 6 34537802 34556333 non-receptive SAM pointed domain containing ETS transcription factor  
HEY2 6 125747664 125761269 non-receptive hes-related family bHLH transcription factor with YRPW motif 2  
EPB41L2 6 130839347 131063322 non-receptive erythrocyte membrane protein band 4.1-like 2  
FNDC1 6 159169397 159272109 non-receptive fibronectin type III domain containing 1  
PRR15 7 29563811 29567295 non-receptive proline rich 15  
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WIPF3 7 29806486 29917066 non-receptive WAS/WASL interacting protein family, member 3  
ADCYAP1R1 7 31052461 31111479 non-receptive adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 
SFRP4 7 37905932 38025695 non-receptive secreted frizzled-related protein 4  
VWC2 7 49773661 49921950 non-receptive von Willebrand factor C domain containing 2  
SEMA3C 7 80742538 80922359 non-receptive sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C  
SEMA3D 7 84995553 85186855 non-receptive sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3D  
COL1A2 7 94394561 94431232 non-receptive collagen, type I, alpha 2  
DYNC1I1 7 95772506 96110071 non-receptive dynein, cytoplasmic 1, intermediate chain 1  
LRRC17 7 102912991 102944949 non-receptive leucine rich repeat containing 17  
NRCAM 7 108147626 108456717 non-receptive neuronal cell adhesion molecule  
ATP6V0A4 7 138706295 138798196 non-receptive ATPase, H+ transporting, lysosomal V0 subunit a4  
TMEM213 7 138797952 138838101 non-receptive transmembrane protein 213  
SOX7 8 10723768 10730512 non-receptive SRY (sex determining region Y)-box 7  
NEFM 8 24913012 24919098 non-receptive neurofilament, medium polypeptide  
NEFL 8 24950955 24957110 non-receptive neurofilament, light polypeptide  
SFRP1 8 41261958 41309497 non-receptive secreted frizzled-related protein 1  
SOX17 8 54457935 54460888 non-receptive SRY (sex determining region Y)-box 17  
CRISPLD1 8 74984515 75034558 non-receptive cysteine-rich secretory protein LCCL domain containing 1  
SLC26A7 8 91209495 91398152 non-receptive solute carrier family 26 (anion exchanger), member 7  
PIP5K1B 9 68705414 69009175 non-receptive phosphatidylinositol-4-phosphate 5-kinase, type I, beta  
FBP1 9 94603133 94640249 non-receptive fructose-1,6-bisphosphatase 1  
GALNT12 9 98807699 98850081 non-receptive polypeptide N- acetylgalactosaminyltransferase 12  
GRIN3A 9 101569353 101738580 non-receptive glutamate receptor, ionotropic, N-methyl-D- aspartate 3A  
FRRS1L 9 109130293 109167291 non-receptive ferric-chelate reductase 1-like  
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RNF183 9 113297093 113303271 non-receptive ring finger protein 183  
OLFM1 9 135075422 135121179 non-receptive olfactomedin 1  
SAPCD2 9 137062124 137070588 non-receptive suppressor APC domain containing 2  
FAM13C 10 59246129 59363181 non-receptive family with sequence similarity 13, member C  
ANK3 10 60026298 60733490 non-receptive ankyrin 3, node of Ranvier (ankyrin G)  
TMEM26 10 61406647 61453450 non-receptive transmembrane protein 26  
UNC5B 10 71212570 71302864 non-receptive unc-5 homolog B (C. elegans)  
KAZALD1 10 101061841 101065592 non-receptive Kazal-type serine peptidase inhibitor domain 1  
DMBT1 10 122560665 122643736 non-receptive deleted in malignant brain tumors 1  
ADAM12 10 126012381 126388455 non-receptive ADAM metallopeptidase domain 12  
B4GALNT4 11 369804 382116 non-receptive beta-1,4-N-acetyl-galactosaminyl transferase 4  
GAS2 11 22625642 22813055 non-receptive growth arrest-specific 2  
MPPED2 11 30384493 30586872 non-receptive metallophosphoesterase domain containing 2  
SLC43A1 11 57484534 57515786 non-receptive solute carrier family 43 (amino acid system L transporter), member 1  
RCOR2 11 63911221 63916844 non-receptive REST corepressor 2  
ANO1 11 70078302 70189528 non-receptive anoctamin 1, calcium activated chloride channel  
PLEKHB1 11 73646178 73662819 non-receptive pleckstrin homology domain containing, family B (evectins) member 1 
TENM4 11 78652831 79440651 non-receptive teneurin transmembrane protein 4  
DLG2 11 83455012 85627270 non-receptive discs, large homolog 2 (Drosophila)  
LOH12CR2 12 12355406 12357067 non-receptive loss of heterozygosity, 12, chromosomal region 2 (non-protein coding) 
AQP5 12 49961870 49965681 non-receptive aquaporin 5  
SLC4A8 12 51391317 51515763 non-receptive solute carrier family 4, sodium bicarbonate cotransporter, member 8 
CSRP2 12 76858715 76879060 non-receptive cysteine and glycine-rich protein 2  
BTBD11 12 107318413 107659642 non-receptive BTB (POZ) domain containing 11  
GJB2 13 20187470 20192898 non-receptive gap junction protein, beta 2, 26kDa  
GJB6 13 20221971 20232395 non-receptive gap junction protein, beta 6, 30kDa  
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CCNA1 13 36431830 36442882 non-receptive cyclin A1  
SIAH3 13 45777243 45851736 non-receptive siah E3 ubiquitin protein ligase family member 3  
SLITRK6 13 85792790 85799488 non-receptive SLIT and NTRK-like family, member 6  
STXBP6 14 24809656 25050297 non-receptive syntaxin binding protein 6 (amisyn)  
LINC00645 14 27612588 27639636 non-receptive long intergenic non-protein coding RNA 645  
AKAP6 14 32329273 32837681 non-receptive A kinase (PRKA) anchor protein 6  
NPAS3 14 32934933 33804176 non-receptive neuronal PAS domain protein 3  
LINC00639 14 38749339 38948273 non-receptive long intergenic non-protein coding RNA 639  
DIO2 14 80197527 80387757 non-receptive deiodinase, iodothyronine, type II  
SLC24A4 14 92322581 92501483 non-receptive solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 4 
SERPINA5 14 94561442 94593120 non-receptive serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 
member 5  
GREM1 15 32717974 32745107 non-receptive gremlin 1, DAN family BMP antagonist  
SORD 15 45023104 45077185 non-receptive sorbitol dehydrogenase  
SLC47A1 17 19533462 19579034 non-receptive solute carrier family 47 (multidrug and toxin extrusion), member 1  
PRR15L 17 47951967 47957878 non-receptive proline rich 15-like  
KCNJ2 17 70168673 70180048 non-receptive potassium inwardly-rectifying channel, subfamily J, member 2  
SDK2 17 73334384 73644089 non-receptive sidekick cell adhesion molecule 2  
CLUL1 18 596988 650334 non-receptive clusterin-like 1 (retinal)  
LAMA1 18 6941744 7117814 non-receptive laminin, alpha 1  
SERPINB5 18 63476761 63505085 non-receptive serpin peptidase inhibitor, clade B (ovalbumin), member 5  
CBLN2 18 72536680 72638517 non-receptive cerebellin 2 precursor  
OLFM2 19 9853718 9936552 non-receptive olfactomedin 2  
CRLF1 19 18593237 18606850 non-receptive cytokine receptor-like factor 1  
C5AR2 19 47332147 47347327 non-receptive complement component 5a receptor 2  
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DBP 19 48630030 48637438 non-receptive D site of albumin promoter (albumin D-box) binding protein  
LRRC4B 19 50516892 50568045 non-receptive leucine rich repeat containing 4B  
KLK4 19 50906352 50910738 non-receptive kallikrein-related peptidase 4  
RASSF2 20 4780023 4823645 non-receptive Ras association (RalGDS/AF-6) domain family member 2  
PAK7 20 9537389 9839041 non-receptive p21 protein (Cdc42/Rac)-activated kinase 7  
SYNDIG1 20 24469199 24666616 non-receptive synapse differentiation inducing 1  
KCNG1 20 51003656 51023129 non-receptive potassium voltage-gated channel, subfamily G, member 1  
CBLN4 20 55997440 56005472 non-receptive cerebellin 4 precursor  
RBBP8NL 20 62410237 62427533 non-receptive RBBP8 N-terminal like  
MMP11 22 23772819 23784316 non-receptive matrix metallopeptidase 11 (stromelysin 3)  
PHF21B 22 44881162 45009999 non-receptive PHD finger protein 21B  
MXRA5 X 3308565 3346641 non-receptive matrix-remodelling associated 5  
EGFL6 X 13569605 13633575 non-receptive EGF-like-domain, multiple 6  
HMGN5 X 81113701 81201942 non-receptive high mobility group nucleosome binding domain 5  
PCDH19 X 100291644 100410273 non-receptive protocadherin 19  
GLA X 101397803 101407925 non-receptive galactosidase, alpha  
ARMCX4 X 101488044 101495811 non-receptive armadillo repeat containing, X-linked 4  
TCEAL5 X 103273691 103276872 non-receptive transcription elongation factor A (SII)-like 5  
AFF2 X 148500619 149000663 non-receptive AF4/FMR2 family, member 2  
MEGF6 1 3489920 3611495 receptive multiple EGF-like-domains 6  
DHRS3 1 12567910 12617731 receptive dehydrogenase/reductase (SDR family) member 3  
CDA 1 20588948 20618908 receptive cytidine deaminase  
HTR1D 1 23191895 23194729 receptive 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled  
NCMAP 1 24556111 24609325 receptive noncompact myelin associated protein  
TRNP1 1 26993707 27000898 receptive TMF1-regulated nuclear protein 1  
TTC39A 1 51287258 51345116 receptive tetratricopeptide repeat domain 39A  
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DNAJC6 1 65254462 65415869 receptive DnaJ (Hsp40) homolog, subfamily C, member 6  
GADD45A 1 67685061 67688338 receptive growth arrest and DNA-damage-inducible, alpha  
CHI3L2 1 111200771 111243440 receptive chitinase 3-like 2  
NPR1 1 153678637 153693992 receptive natriuretic peptide receptor 1  
EFNA1 1 155127460 155134857 receptive ephrin-A1  
ACKR1 1 159203307 159206500 receptive atypical chemokine receptor 1 (Duffy blood group)  
CRP 1 159712289 159714589 receptive C-reactive protein, pentraxin-related  
C4BPA 1 207104262 207144972 receptive complement component 4 binding protein, alpha  
CD55 1 207321508 207360966 receptive CD55 molecule, decay accelerating factor for complement (Cromer 
blood group)  
LAMB3 1 209614870 209652466 receptive laminin, beta 3  
G0S2 1 209675420 209676388 receptive G0/G1 switch 2  
TGFB2 1 218346235 218444619 receptive transforming growth factor, beta 2  
CAPN8 1 223538008 223665734 receptive calpain 8  
LEFTY1 1 225886282 225911382 receptive left-right determination factor 1  
CYS1 2 10056780 10080411 receptive cystin 1  
CAPN13 2 30722771 30807446 receptive calpain 13  
LINC01320 2 34677579 34738231 receptive long intergenic non-protein coding RNA 1320  
GNLY 2 85694291 85698854 receptive granulysin  
MALL 2 110083870 110116566 receptive mal, T-cell differentiation protein-like  
PAX8 2 113215997 113278950 receptive paired box 8  
INHBB 2 120346143 120351808 receptive inhibin, beta B  
DPP4 2 161992241 162074542 receptive dipeptidyl-peptidase 4  
NABP1 2 191678136 191696659 receptive nucleic acid binding protein 1  
AOX1 2 200585868 200677064 receptive aldehyde oxidase 1  
TUBA4A 2 219249711 219278170 receptive tubulin, alpha 4a  
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DNER 2 229357629 229714558 receptive delta/notch-like EGF repeat containing  
B3GNT7 2 231395543 231401164 receptive UDP-GlcNAc:betaGal beta-1,3-N- acetylglucosaminyltransferase 7  
THRB 3 24117160 24495282 receptive thyroid hormone receptor, beta  
SLC6A20 3 45755450 45796535 receptive solute carrier family 6 (proline IMINO transporter), member 20  
LINC01212 3 69999577 70015318 receptive long intergenic non-protein coding RNA 1212  
EIF4E3 3 71675416 71754773 receptive eukaryotic translation initiation factor 4E family member 3  
NFKBIZ 3 101827991 101861022 receptive nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, zeta  
ZPLD1 3 102099244 102479841 receptive zona pellucida-like domain containing 1  
GRAMD1C 3 113838418 113947174 receptive GRAM domain containing 1C  
CP 3 149162417 149222055 receptive ceruloplasmin (ferroxidase)  
RARRES1 3 158696892 158732696 receptive retinoic acid receptor responder (tazarotene induced) 1  
THPO 3 184371935 184378144 receptive thrombopoietin  
ST6GAL1 3 186930485 187078553 receptive ST6 beta-galactosamide alpha-2,6- sialyltranferase 1  
BCL6 3 187721377 187745727 receptive B-cell CLL/lymphoma 6  
CLDN1 3 190305701 190322475 receptive claudin 1  
PPARGC1A 4 23792021 23890077 receptive peroxisome proliferator-activated receptor gamma, coactivator 1 alpha 
FGA 4 154583126 154590766 receptive fibrinogen alpha chain  
FGG 4 154604134 154612967 receptive fibrinogen gamma chain  
GUCY1B3 4 155758992 155807591 receptive guanylate cyclase 1, soluble, beta 3  
PTGER4 5 40679498 40693735 receptive prostaglandin E receptor 4 (subtype EP4)  
GZMA 5 55102648 55110252 receptive granzyme A (granzyme 1, cytotoxic T- lymphocyte-associated serine 
esterase 3)  
IL6ST 5 55935095 55994993 receptive interleukin 6 signal transducer  
ANKRD55 5 56099678 56233359 receptive ankyrin repeat domain 55  
ELOVL7 5 60751791 60844389 receptive ELOVL fatty acid elongase 7  
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SLCO4C1 5 102233986 102296549 receptive solute carrier organic anion transporter family, member 4C1  
CXCL14 5 135570679 135579279 receptive chemokine (C-X-C motif) ligand 14  
SPINK1 5 147824568 147831786 receptive serine peptidase inhibitor, Kazal type 1  
GPX3 5 151020438 151028993 receptive glutathione peroxidase 3 (plasma)  
HAVCR1 5 157029413 157059119 receptive hepatitis A virus cellular receptor 1  
GFOD1 6 13357830 13487662 receptive glucose-fructose oxidoreductase domain containing 1  
PRL 6 22287244 22297501 receptive prolactin  
RNF39 6 30070266 30075887 receptive ring finger protein 39  
VWA7 6 31765590 31777294 receptive von Willebrand factor A domain containing 7  
SLC44A4 6 31863192 31879046 receptive solute carrier family 44, member 4  
UNC5CL 6 41026911 41039217 receptive unc-5 homolog C (C. elegans)-like  
GPR110 6 46997703 47042363 receptive G protein-coupled receptor 110  
VNN1 6 132681590 132714049 receptive vanin 1  
ALDH8A1 6 134917390 134950122 receptive aldehyde dehydrogenase 8 family, member A1  
MAP3K5 6 136557047 136792518 receptive mitogen-activated protein kinase kinase kinase 5  
CITED2 6 139371807 139374620 receptive Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 2  
PPP1R14C 6 150143076 150250357 receptive protein phosphatase 1, regulatory (inhibitor) subunit 14C  
SOD2 6 159669057 159762529 receptive superoxide dismutase 2, mitochondrial  
THBS2 6 169215780 169254044 receptive thrombospondin 2  
SCIN 7 12570686 12653603 receptive scinderin  
SNX10 7 26291895 26374329 receptive sorting nexin 10  
ADCY1 7 45574140 45723116 receptive adenylate cyclase 1 (brain)  
ABCA13 7 48171460 48647496 receptive ATP-binding cassette, sub-family A (ABC1), member 13  
CLDN4 7 73827744 73832693 receptive claudin 4  
FGL2 7 77193371 77199826 receptive fibrinogen-like 2  
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CYP3A5 7 99648194 99679998 receptive cytochrome P450, family 3, subfamily A, polypeptide 5  
MET 7 116672390 116798386 receptive MET proto-oncogene, receptor tyrosine kinase  
CPA4 7 130293134 130324180 receptive carboxypeptidase A4  
TMEM140 7 135148072 135166215 receptive transmembrane protein 140  
NOS3 7 150990995 151014588 receptive nitric oxide synthase 3 (endothelial cell)  
MTMR7 8 17298030 17413327 receptive myotubularin related protein 7  
SLC7A2 8 17497088 17570573 receptive solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2  
STC1 8 23841915 23854807 receptive stanniocalcin 1  
IDO1 8 39902275 39928431 receptive indoleamine 2,3-dioxygenase 1  
CEBPD 8 47736909 47739086 receptive CCAAT/enhancer binding protein (C/EBP), delta  
RGS20 8 53851808 53959303 receptive regulator of G-protein signaling 20  
FAM84B 8 126552442 126558393 receptive family with sequence similarity 84, member B  
DOCK8 9 214865 465259 receptive dedicator of cytokinesis 8  
SLC1A1 9 4490444 4587469 receptive solute carrier family 1 (neuronal/epithelial high affinity glutamate 
transporter, system Xag), member 1  
LURAP1L 9 12775021 12822131 receptive leucine rich adaptor protein 1-like  
AQP3 9 33441154 33447611 receptive aquaporin 3 (Gill blood group)  
TMEM252 9 68536580 68540867 receptive transmembrane protein 252  
GAS1 9 86944363 86947189 receptive growth arrest-specific 1  
DAPK1 9 87497228 87708633 receptive death-associated protein kinase 1  
PAEP 9 135561758 135566955 receptive progestagen-associated endometrial protein  
LINC01502 9 135574935 135587112 receptive long intergenic non-protein coding RNA 1502  
KLF6 10 3775996 3785281 receptive Kruppel-like factor 6  
PHYHIPL 10 59176590 59247774 receptive phytanoyl-CoA 2-hydroxylase interacting protein-like  
ARID5B 10 61901300 62096944 receptive AT rich interactive domain 5B (MRF1-like)  
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TSPAN15 10 69451473 69507669 receptive tetraspanin 15  
RBP4 10 93591687 93601744 receptive retinol binding protein 4, plasma  
COL17A1 10 104031286 104086002 receptive collagen, type XVII, alpha 1  
SORCS1 10 106573663 107164534 receptive sortilin-related VPS10 domain containing receptor 1  
ADRA2A 10 111077163 111080907 receptive adrenoceptor alpha 2A  
HABP2 10 113550837 113589602 receptive hyaluronan binding protein 2  
SLC18A2 10 117241093 117279430 receptive solute carrier family 18 (vesicular monoamine transporter), member 2 
ACADSB 10 123008979 123058311 receptive acyl-CoA dehydrogenase, short/branched chain  
SERPING1 11 57597387 57614853 receptive serpin peptidase inhibitor, clade G (C1 inhibitor), member 1  
RARRES3 11 63536816 63546462 receptive retinoic acid receptor responder (tazarotene induced) 3  
PLA2G16 11 63573195 63614469 receptive phospholipase A2, group XVI  
CTSW 11 65879809 65883741 receptive cathepsin W  
NNMT 11 114257831 114313285 receptive nicotinamide N-methyltransferase  
TAGLN 11 117199321 117204782 receptive transgelin  
SLC6A12 12 190077 214120 receptive solute carrier family 6 (neurotransmitter transporter), member 12  
B4GALNT3 12 460364 563509 receptive beta-1,4-N-acetyl-galactosaminyl transferase 3  
CLEC4E 12 8533305 8540963 receptive C-type lectin domain family 4, member E  
MFAP5 12 8637346 8662884 receptive microfibrillar associated protein 5  
RIMKLB 12 8697177 8783085 receptive ribosomal modification protein rimK-like family member B  
ERP27 12 14914035 14939082 receptive endoplasmic reticulum protein 27  
KRT7 12 52233114 52248921 receptive keratin 7  
AVIL 12 57797882 57818704 receptive advillin  
PTPRR 12 70638073 70920843 receptive protein tyrosine phosphatase, receptor type, R  
TSPAN8 12 71125085 71441898 receptive tetraspanin 8  
PPFIA2 12 81257975 81759553 receptive protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), 
interacting protein (liprin), alpha 2  
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HAL 12 95972662 95996365 receptive histidine ammonia-lyase  
HNF1A-AS1 12 120941728 120980965 receptive HNF1A antisense RNA 1  
SLC15A4 12 128793191 128823983 receptive solute carrier family 15 (oligopeptide transporter), member 4  
GLT1D1 12 128853494 128984968 receptive glycosyltransferase 1 domain containing 1  
PCDH17 13 57631812 57729311 receptive protocadherin 17  
EDNRB 13 77895481 77919768 receptive endothelin receptor type B  
SLC15A1 13 98683801 98752654 receptive solute carrier family 15 (oligopeptide transporter), member 1  
RNASE4 14 20684100 20701215 receptive ribonuclease, RNase A family, 4  
ANG 14 20684177 20694186 receptive angiogenin, ribonuclease, RNase A family, 5  
PTGER2 14 52314305 52328606 receptive prostaglandin E receptor 2 (subtype EP2), 53kDa  
KCNH5 14 62699454 63101866 receptive potassium voltage-gated channel, subfamily H (eag-related), member 5 
SYNE2 14 63852983 64226433 receptive spectrin repeat containing, nuclear envelope 2  
PAPLN 14 73237497 73274640 receptive papilin, proteoglycan-like sulfated glycoprotein  
TMEM63C 14 77116568 77259495 receptive transmembrane protein 63C  
CATSPERB 14 91580774 91780707 receptive catsper channel auxiliary subunit beta  
TNFAIP2 14 103123461 103137439 receptive tumor necrosis factor, alpha-induced protein 2  
BCL2L10 15 52109263 52112775 receptive BCL2-like 10 (apoptosis facilitator)  
LIPC 15 58410569 58569843 receptive lipase, hepatic  
C2CD4B 15 62163535 62165283 receptive C2 calcium-dependent domain containing 4B  
ST20 15 79898840 79923702 receptive suppressor of tumorigenicity 20  
BCL2A1 15 79960889 79971446 receptive BCL2-related protein A1  
FAM169B 15 98437162 98514382 receptive family with sequence similarity 169, member B  
TMC5 16 19410539 19499113 receptive transmembrane channel-like 5  
IL4R 16 27313668 27364778 receptive interleukin 4 receptor  
GSG1L 16 27787535 28063509 receptive GSG1-like  
NUPR1 16 28532708 28539174 receptive nuclear protein, transcriptional regulator, 1  
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IRX3 16 54283304 54286763 receptive iroquois homeobox 3  
IRX5 16 54930862 54934485 receptive iroquois homeobox 5  
MT2A 16 56608199 56609497 receptive metallothionein 2A  
MT1E 16 56625475 56627112 receptive metallothionein 1E  
CDH3 16 68644836 68722616 receptive cadherin 3, type 1, P-cadherin (placental)  
HAS3 16 69105564 69118719 receptive hyaluronan synthase 3  
CDYL2 16 80597906 80804329 receptive chromodomain protein, Y-like 2  
ALOX12 17 6996065 7010736 receptive arachidonate 12-lipoxygenase  
ACAP1 17 7336529 7351478 receptive ArfGAP with coiled-coil, ankyrin repeat and PH domains 1  
CD68 17 7579467 7582113 receptive CD68 molecule  
DDX52 17 37609778 37643464 receptive DEAD (Asp-Glu-Ala-Asp) box polypeptide 52  
HNF1B 17 37686432 37745247 receptive HNF1 homeobox B  
GRB7 17 39737927 39747291 receptive growth factor receptor-bound protein 7  
GAST 17 41712326 41715969 receptive gastrin  
HAP1 17 41717742 41734644 receptive huntingtin-associated protein 1  
MPP3 17 43800799 43833170 receptive membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3) 
ITGB3 17 47253846 47344292 receptive integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)  
B4GALNT2 17 49132460 49169989 receptive beta-1,4-N-acetyl-galactosaminyl transferase 2  
ITGA3 17 50056110 50090481 receptive integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 
TMEM92 17 50271406 50281485 receptive transmembrane protein 92  
ABCC3 17 50634777 50692252 receptive ATP-binding cassette, sub-family C (CFTR/MRP), member 3  
ERN1 17 64039142 64130819 receptive endoplasmic reticulum to nucleus signaling 1  
ABCA6 17 69078702 69141888 receptive ATP-binding cassette, sub-family A (ABC1), member 6  
SOCS3 17 78356778 78360077 receptive suppressor of cytokine signaling 3  
DLGAP1-AS3 18 3878180 3897069 receptive DLGAP1 antisense RNA 3  
IMPA2 18 11981037 12030883 receptive inositol(myo)-1(or 4)-monophosphatase 2  
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GATA6 18 22169443 22202528 receptive GATA binding protein 6  
ALPK2 18 58481247 58628957 receptive alpha-kinase 2  
C3 19 6677704 6730562 receptive complement component 3  
COMP 19 18782773 18791314 receptive cartilage oligomeric matrix protein  
RHPN2 19 32978593 33064888 receptive rhophilin, Rho GTPase binding protein 2  
FXYD3 19 35115879 35124324 receptive FXYD domain containing ion transport regulator 3  
PSG9 19 43211791 43269530 receptive pregnancy specific beta-1-glycoprotein 9  
LYPD3 19 43460787 43465660 receptive LY6/PLAUR domain containing 3  
KIR2DL4 19 54803535 54814517 receptive killer cell immunoglobulin-like receptor, two domains, long cytoplasmic 
tail, 4  
THBD 20 23045633 23049741 receptive thrombomodulin  
LBP 20 38346356 38377023 receptive lipopolysaccharide binding protein  
SLPI 20 45252239 45254564 receptive secretory leukocyte peptidase inhibitor  
KCNB1 20 49363877 49482647 receptive potassium voltage-gated channel, Shab- related subfamily, member 1  
CYP24A1 20 54153449 54173973 receptive cytochrome P450, family 24, subfamily A, polypeptide 1  
SLCO4A1 20 62642445 62672295 receptive solute carrier organic anion transporter family, member 4A1  
TMEM1 21 5155499 5163695 receptive TMEM1 protein {ECO:0000313|EMBL:BAA21136.1}  
SGSM1 22 24806169 24927578 receptive small G protein signaling modulator 1  
LIF 22 30240447 30246851 receptive leukemia inhibitory factor  
WNT7B 22 45920362 45977129 receptive wingless-type MMTV integration site family, member 7B  
TYMP 22 50525752 50530085 receptive thymidine phosphorylase  
CSF2RA X 1268800 1310381 receptive colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage)  
MAOA X 43654907 43746824 receptive monoamine oxidase A  
LINC00890 X 111511662 111522399 receptive long intergenic non-protein coding RNA 890  
GABRE X 151953124 151974679 receptive gamma-aminobutyric acid (GABA) A receptor, epsilon  
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Supplementary Table 2 Stromal cell signature genes. List of genes in the stromal cell signature that was developed from cultured stromal cells. 
Gene Chr Start End Description 
COL24A1 1 85729233 86156943 collagen, type XXIV, alpha 1  
DPT 1 168695459 168729264 dermatopontin  
AFF3 2 99545419 100142739 AF4/FMR2 family, member 3  
HOXD10 2 176108790 176119942 homeobox D10  
HOXD9 2 176122720 176124937 homeobox D9  
ZNF804A 2 184598366 184939492 zinc finger protein 804A  
LINC01391 3 138935189 138944020 long intergenic non-protein coding RNA 1391  
FOXL2 3 138944224 138947140 forkhead box L2  
SLC9A9 3 143265222 143848531 solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9  
HTRA3 4 8269765 8307111 HtrA serine peptidase 3  
GPR78 4 8558725 8619761 G protein-coupled receptor 78  
CPZ 4 8592660 8619759 carboxypeptidase Z  
C1QTNF7 4 15339818 15446166 C1q and tumor necrosis factor related protein 7  
ADAMTS12 5 33523535 33892192 ADAM metallopeptidase with thrombospondin type 1 motif, 12  
CASC15 6 21664772 22214505 cancer susceptibility candidate 15 (non- protein coding)  
TREM1 6 41267926 41286719 triggering receptor expressed on myeloid cells 1  
HOXA5 7 27141052 27143668 homeobox A5  
HOXA9 7 27162435 27175180 homeobox A9  
HOXA10-HOXA9 7 27163535 27180013 Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000421799}  
TRBC2 7 142670777 142802748 T cell receptor beta constant 2  
RUNX1T1 8 91954967 92103286 runt-related transcription factor 1; translocated to, 1 (cyclin D-related)  
HAS2 8 121612116 121641390 hyaluronan synthase 2  
TEK 9 27109141 27230175 TEK tyrosine kinase, endothelial  
TMEM215 9 32783499 32787399 transmembrane protein 215  
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VSTM4 10 49014245 49115509 V-set and transmembrane domain containing 4  
HPSE2 10 98457077 99235862 heparanase 2 (inactive)  
DPYSL4 10 132186900 132205776 dihydropyrimidinase-like 4  
SLC1A2 11 35251206 35420063 solute carrier family 1 (glial high affinity glutamate transporter), member 2  
NOX4 11 89324356 89498187 NADPH oxidase 4  
CASP1 11 105025443 105035250 caspase 1, apoptosis-related cysteine peptidase  
KIF5A 12 57549998 57586632 kinesin family member 5A  
ATP8A2 13 25372071 26025851 ATPase, aminophospholipid transporter, class I, type 8A, member 2  
RP11-404P21.8 14 96204844 96263929 Uncharacterized protein {ECO:0000313|Ensembl:ENSP00000450984}  
CACNA1H 16 1153241 1221771 calcium channel, voltage-dependent, T type, alpha 1H subunit  
FOXF1 16 86510527 86515418 forkhead box F1  
TBX2 17 61399896 61409466 T-box 2  
PIEZO2 18 10666483 11148762 piezo-type mechanosensitive ion channel component 2  
FBXO17 19 38941401 38975910 F-box protein 17  
ADAM33 20 3667965 3682246 ADAM metallopeptidase domain 33  
KIAA1755 20 38210488 38260772 KIAA1755  
RP11-524D16__A.3 X 100673330 100673981 No description 
MUM1L1 X 106168305 106208956 melanoma associated antigen (mutated) 1-like 1  
LINC00890 X 111511662 111522399 long intergenic non-protein coding RNA 890  
FHL1 X 136147400 136211359 four and a half LIM domains 1  
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Supplementary Table 3 Epithelial cell signature genes. List of genes in the epithelial cell signature that was developed from epithelial cell 
organoids. Genes marked as non-receptive are upregulated in the non-receptive state and genes marked receptive are upregulated in the receptive state. 
Gene Chr Start End Upregulated in: Description 
SYTL1 1 27342020 27353937 non-receptive synaptotagmin-like 1  
GJB3 1 34781189 34786369 non-receptive gap junction protein, beta 3, 31kDa  
PCSK9 1 55039548 55064852 non-receptive proprotein convertase subtilisin/kexin type 9  
DENND2D 1 111187174 111204535 non-receptive DENN/MADD domain containing 2D  
RAB25 1 156061160 156070514 non-receptive RAB25, member RAS oncogene family  
TSTD1 1 161037631 161038990 non-receptive thiosulfate sulfurtransferase (rhodanese)- like domain containing 1  
SLC26A9 1 205913048 205943460 non-receptive solute carrier family 26 (anion exchanger), member 9  
GRHL1 2 9951693 10002277 non-receptive grainyhead-like 1 (Drosophila)  
LYPD6B 2 149038107 149215262 non-receptive LY6/PLAUR domain containing 6B  
LY75 2 159803355 159904749 non-receptive lymphocyte antigen 75  
NUP210 3 13316235 13420309 non-receptive nucleoporin 210kDa  
WNT7A 3 13816258 13880121 non-receptive wingless-type MMTV integration site family, member 7A  
FAM107A 3 58564117 58627610 non-receptive family with sequence similarity 107, member A  
MECOM 3 169083499 169663618 non-receptive MDS1 and EVI1 complex locus  
FGFBP1 4 15935569 15938740 non-receptive fibroblast growth factor binding protein 1  
C4orf19 4 37453941 37623495 non-receptive chromosome 4 open reading frame 19  
CXCL5 4 73995642 73998779 non-receptive chemokine (C-X-C motif) ligand 5  
ANXA3 4 78551519 78610451 non-receptive annexin A3  
SH3RF2 5 145936579 146081791 non-receptive SH3 domain containing ring finger 2  
FAT2 5 151504093 151568944 non-receptive FAT atypical cadherin 2  
GCNT2 6 10492223 10629368 non-receptive glucosaminyl (N-acetyl) transferase 2, I- branching enzyme 
CLIC5 6 45898451 46080395 non-receptive chloride intracellular channel 5  
ENPP4 6 46129993 46146699 non-receptive ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative)  
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DLX6-AS1 7 96955141 97014065 non-receptive DLX6 antisense RNA 1  
CFTR 7 117465784 117715971 non-receptive cystic fibrosis transmembrane conductance regulator (ATP-binding 
cassette sub-family C, member 7)  
SOX17 8 54457935 54460888 non-receptive SRY (sex determining region Y)-box 17  
CALB1 8 90058608 90095475 non-receptive calbindin 1, 28kDa  
GRHL2 8 101492432 101669726 non-receptive grainyhead-like 2 (Drosophila)  
SYK 9 90801787 90898549 non-receptive spleen tyrosine kinase  
PTPN3 9 109375466 109498313 non-receptive protein tyrosine phosphatase, non-receptor type 3  
MUC6 11 1012821 1036706 non-receptive mucin 6, oligomeric mucus/gel-forming  
MUC5AC 11 1157953 1201138 non-receptive mucin 5AC, oligomeric mucus/gel-forming  
CDC42BPG 11 64823387 64844569 non-receptive CDC42 binding protein kinase gamma (DMPK- like)  
AQP5 12 49961870 49965681 non-receptive aquaporin 5  
NOS1 12 117208142 117452170 non-receptive nitric oxide synthase 1 (neuronal)  
MCF2L 13 112894378 113099739 non-receptive MCF.2 cell line derived transforming sequence-like  
ERN2 16 23690326 23713500 non-receptive endoplasmic reticulum to nucleus signaling 2  
MARVELD3 16 71626161 71642114 non-receptive MARVEL domain containing 3  
PPP1R1B 17 39626740 39636626 non-receptive protein phosphatase 1, regulatory (inhibitor) subunit 1B  
HOXB8 17 48611377 48614939 non-receptive homeobox B8  
HOXB9 17 48621159 48626356 non-receptive homeobox B9  
RNF43 17 58352500 58417595 non-receptive ring finger protein 43  
EVPL 17 76004502 76027452 non-receptive envoplakin  
LIPG 18 49560699 49599182 non-receptive lipase, endothelial  
ONECUT3 19 1752373 1780988 non-receptive one cut homeobox 3  
TJP3 19 3708109 3750813 non-receptive tight junction protein 3  
CEACAM5 19 41576273 41729798 non-receptive carcinoembryonic antigen-related cell adhesion molecule 5  
CEACAM6 19 41750977 41772208 non-receptive carcinoembryonic antigen-related cell adhesion molecule 6 (non-
specific cross reacting antigen)  
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FAM83F 22 39994949 40043529 non-receptive family with sequence similarity 83, member F  
SLC6A14 X 116436622 116461458 non-receptive solute carrier family 6 (amino acid transporter), member 14  
SMPDL3B 1 27934993 27959157 receptive sphingomyelin phosphodiesterase, acid-like 3B  
TACSTD2 1 58575423 58577773 receptive tumor-associated calcium signal transducer 2  
ERICH3 1 74568111 74673738 receptive glutamate-rich 3  
S100A14 1 153614255 153616986 receptive S100 calcium binding protein A14  
C1orf116 1 207018521 207032756 receptive chromosome 1 open reading frame 116  
CAPN13 2 30722771 30820542 receptive calpain 13  
TGFA 2 70447280 70554193 receptive transforming growth factor, alpha  
RAB17 2 237574322 237601614 receptive RAB17, member RAS oncogene family  
SLC6A20 3 45755450 45796535 receptive solute carrier family 6 (proline IMINO transporter), member 20  
RASSF6 4 73571550 73620631 receptive Ras association (RalGDS/AF-6) domain family member 6  
FGF18 5 171419656 171457623 receptive fibroblast growth factor 18  
RNF144B 6 18387350 18468874 receptive ring finger protein 144B  
SLC44A4 6 31863192 31879046 receptive solute carrier family 44, member 4  
KCNK5 6 39188973 39229450 receptive potassium channel, subfamily K, member 5  
MACC1 7 20134655 20217404 receptive metastasis associated in colon cancer 1  
RAPGEF5 7 22118238 22357144 receptive Rap guanine nucleotide exchange factor (GEF) 5  
CPVL 7 28995231 29195451 receptive carboxypeptidase, vitellogenic-like  
SBSPON 8 73064540 73124088 receptive somatomedin B and thrombospondin, type 1 domain containing  
AQP3 9 33441154 33447611 receptive aquaporin 3 (Gill blood group)  
LCN2 9 128149071 128153455 receptive lipocalin 2  
HKDC1 10 69220303 69267559 receptive hexokinase domain containing 1  
COL17A1 10 104031286 104086002 receptive collagen, type XVII, alpha 1  
PKP3 11 392614 404908 receptive plakophilin 3  
IL18 11 112143251 112164117 receptive interleukin 18  
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MPZL3 11 118226690 118252350 receptive myelin protein zero-like 3  
TMEM45B 11 129815819 129860003 receptive transmembrane protein 45B  
GLB1L2 11 134331874 134378341 receptive galactosidase, beta 1-like 2  
RASAL1 12 113098819 113136239 receptive RAS protein activator like 1 (GAP1 like)  
TESC 12 117038923 117099479 receptive tescalcin  
TMEM233 12 119593459 119643066 receptive transmembrane protein 233  
SCEL 13 77535674 77645263 receptive sciellin  
GPX2 14 64939152 64942905 receptive glutathione peroxidase 2 (gastrointestinal)  
SERPINA1 14 94376747 94390693 receptive serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1  
SLC27A2 15 50182196 50236395 receptive solute carrier family 27 (fatty acid transporter), member 2  
PRSS33 16 2783953 2787948 receptive protease, serine, 33  
TOX3 16 52438005 52547802 receptive TOX high mobility group box family member 3  
CDH3 16 68636189 68722616 receptive cadherin 3, type 1, P-cadherin (placental)  
CHST6 16 75472052 75495384 receptive carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6  
ATP2C2 16 84368527 84464187 receptive ATPase, Ca++ transporting, type 2C, member 2  
TNS4 17 40475828 40501597 receptive tensin 4  
SIGLEC15 18 45825512 45844080 receptive sialic acid binding Ig-like lectin 15  
MISP 19 751126 764319 receptive mitotic spindle positioning  
LRG1 19 4536409 4540474 receptive leucine-rich alpha-2-glycoprotein 1  
CTD-2396E7.11 19 6469465 6470152 receptive No description 
SH2D3A 19 6752160 6767588 receptive SH2 domain containing 3A  
MUC16 19 8848844 8981342 receptive mucin 16, cell surface associated  
B3GNT3 19 17794828 17813082 receptive UDP-GlcNAc:betaGal beta-1,3-N- acetylglucosaminyltransferase 3  
FOXA2 20 22581005 22585455 receptive forkhead box A2  
PRODH 22 18912777 18936553 receptive proline dehydrogenase (oxidase) 1  
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Supplementary Table 4 Enriched Motif IDs for bivalent regions that resolved to 
H3K4me3-only in the receptive state. Analysis was carried out using JASPAR2018 and 
HOMCOMOCOv11 motif databases. Analysis was further refined by factors having to be 
present in both datasets. Adjusted p-value for each motif and database displayed. 
Motif ID Adjusted p-value Motif ID Adjusted p-value 
JASPAR2018 
CORE 












E2F6 1.20E-02 4.09E-10 KLF4 3.94E-03 3.78E-07 
EHF 2.58E-04 5.68E-14 KLF5 7.22E-09 9.47E-17 
ELF1 1.04E-02 2.71E-11 KLF9 3.83E-11 3.17E-03 
ELF5 6.02E-10 2.64E-15 MEF2A 3.98E-05 2.56E-03 
ERG 1.34E-03 5.50E-21 MEF2B 1.32E-02 8.42E-03 
ETS1 3.80E-04 4.14E-16 MEF2C 1.09E-03 4.47E-03 
FOXA1 3.00E-04 6.02E-05 MEF2D 8.27E-03 2.83E-04 
FOXA2 2.64E-05 3.83E-04 MYOD1 7.97E-03 5.94E-04 
FOXJ3 2.90E-03 5.29E-06 MYOG 9.50E-04 4.35E-03 
FOXK1 3.96E-08 1.35E-08 SOX3 3.64E-07 7.57E-06 
FOXO1 1.55E-04 4.09E-07 SP1 1.45E-08 1.47E-09 
FOXP1 1.68E-04 4.82E-09 SP2 1.98E-08 1.09E-13 
FOXP2 3.92E-07 3.08E-05 SP3 2.47E-04 1.30E-13 
GABPA 5.08E-05 3.81E-05 SP4 1.45E-03 4.04E-20 
HIF1A 1.39E-02 3.12E-03 SPIB 1.56E-11 4.06E-04 
IRF1 4.40E-10 9.45E-10 STAT1 9.34E-03 2.79E-03 
IRF3 1.73E-05 1.84E-27 STAT4 1.21E-04 2.07E-06 
IRF7 1.39E-02 6.05E-07 TBP 3.03E-03 9.83E-03 
KLF1 7.93E-04 6.44E-12 ZEB1 2.52E-04 2.62E-06 
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Supplementary Table 5 Additional DNA modifiers expression in the endometrium. 
DESeq2 and/or EdgeR corrected p values for genes involved in the base excision repair 
pathway. Expression of genes in LCM coupled with RNA-seq of epithelial cells between 
LH+5 and LH+8 (Salker et al. 2017). As well as the expression in my whole tissue RNA-
sequencing data comparing non-receptive with receptive samples. 
 LCM RNA-seq 
Epithelial cells 
LH+5 vs LH+8 
My RNA-seq data 
from Whole Tissue 
Samples 
NR vs R Gene DESeq2 p value DESeq2             
p value 
EdgeR             
p value UHRF1 1 0.808 1 
MBD2 0.728 0.289 0.356 
POLB 1 0.543 0.907 
XRCC1 1 0.417 0.611 
APEX1 1 0.149 0.509 
MPG 1 0.292 0.722 
OGG1 1 0.867 1 
SMUG1 1 0.877 1 
TDG 1 0.945 1 
NEIL1 1 0.813 1 
PARP1 1 0.415 0.794 
	
	
Supplementary Table 6 Extended Hippo pathway genes and associated differential 5mC 
or 5hmC genes. A list of KEGG Hippo signalling pathway genes (column one and two, 
https://www.genome.jp/dbget-bin/www_bget?pathway+hsa04390). The genes associated with 
differential 5mC between non-receptive control and endometriosis samples (column three) 
and between receptive control and endometriosis samples (column four). Genes associated 
with differential 5hmC between non-receptive control and endometriosis samples (column 
five), and between receptive control and endometriosis samples (column six). 









RC v RE 
ACTB MYC ACTB APC BMP2 APC 
ACTG1 NF2 BMP8A BMP5 BMP5 BBC3 
AFP NKD1 BMPR1A BMPR1A BMP6 BMPR1A 
AJUBA PARD3 BMPR1B BMPR1B BMPR1B BMPR1B 
AMH PARD6A CRB1 BMPR2 BMPR2 CDH1 
AMOT  PARD6B CTNNA1 BTRC BTRC CTNNA1 
APC PARD6G CTNNA2 CCND2 CRB1 CTNNA2 
APC2  PATJ CTNNA3 CRB1 CTNNA1 CTNNA3 
AREG PPP1CA DLG1 CSNK1E CTNNA2 DLG2 
AXIN1 PPP1CB DLG2 CTGF CTNNA3 FBXW11 
AXIN2 PPP1CC FRMD6 CTNNA1 DLG2 FRMD6 
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BBC3 PPP2CA GSK3B CTNNA2 NKD1 GSK3B 
BIRC2 PPP2CB LATS1 CTNNA3 PPP2R1B LATS2 
BIRC5 PPP2R1A LEF1 DLG2 PPP2R2A LEF1 
BMP2 PPP2R1B PARD3 FBXW11 PPP2R2D PARD3 
BMP4 PPP2R2A PPP2CA FGF1 PRKCI PARD6G 
BMP5 PPP2R2B PPP2CB FZD1 SMAD4 PPP1CB 
BMP6 PPP2R2C PPP2R2B GDF5 STK3 PPP2CA 
BMP7 PPP2R2D SMAD2 GSK3B TCF7L2 PPP2R2B 
BMP8A PRKCI SMAD4 LEF1 TGFBR2 SMAD1 
BMP8B PRKCZ STK3 LIMD1 TP53BP2 SMAD4 
BMPR1A RASSF1 TCF7 LLGL2 WNT8B STK3 
BMPR1B RASSF6 TCF7L2 MOB1B   TGFBR1 
BMPR2 SAV1 TEAD1 MPP5   TGFBR2 
BTRC SCRIB TGFBR2 NKD1   WWC1 
CCND1 SERPINE1 WNT10A PARD3   WWTR1 
CCND2 SMAD1 WNT4 PPP1CB     
CCND3 SMAD2 WNT5B PPP2CA     
CDH1 SMAD3 WNT7B PPP2CB     
CRB1 SMAD4 WWC1 PPP2R1A     
CRB2 SMAD7 WWTR1 PPP2R2B     
CSNK1D SNAI2 YAP1 PRKCZ     
CSNK1E SOX2 YWHAB RASSF6     
CTGF STK3 YWHAZ SAV1     
CTNNA1 TCF7   SMAD1     
CTNNA2 TCF7L1   SMAD4     
CTNNA3 TCF7L2   STK3     
CTNNB1 TEAD1   TCF7L1     
DLG1 TEAD2   TCF7L2     
DLG2 TEAD3   TEAD1     
DLG3 TEAD4   TGFB2     
DLG4 TGFB1   TGFBR1     
DVL1 TGFB2   TGFBR2     
DVL2 TGFB3   WNT10B     
DVL3 TGFBR1   WNT9B     
FBXW11 TGFBR2   WWC1     
FGF1 TP53BP2   WWTR1     
FRMD1 TP73         
FRMD6 WNT1         
FZD1 WNT10A         
FZD10 WNT10B         
FZD2 WNT11         
FZD3 WNT16         
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FZD4 WNT2          
FZD5 WNT2B         
FZD6 WNT3         
FZD7 WNT3A         
FZD8 WNT4         
FZD9 WNT5A         
GDF5 WNT5B         
GDF6 WNT6         
GDF7 WNT7A         
GLI2 WNT7B         
GSK3B WNT8A         
ID1 WNT8B         
ID2 WNT9A         
ITGB2 WNT9B         
LATS1 WTIP         
LATS2 WWC1         
LEF1 WWTR1         
LIMD1 YAP1         
LLGL1 YWHAB         
LLGL2 YWHAE         
CSNK1E   YWHAG         
MOB1A YWHAH         
MOB1B YWHAQ         
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